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FDA The Food and Drug Administration of the United States  
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VEGF  vascular endothelial growth factor 
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1. INTRODUCTION 
Already at the end of 19th century Paul Ehrlich discovered the vascular barrier 
between blood circulation and central nervous system as he observed that 
certain dyes when injected into vascular system stain all the organs except brain 
and spinal cord (Ehrlich 2013). Now it is well-known that protecting barriers 
exist in order to help maintain brain homeostasis and prevent the entrance of 
pathogens and toxic compounds (Engelhardt and Sorokin 2009). The same 
barriers limit the entrance of 98% of molecules, including most of the drugs into 
the brain tissue (Wolburg et al. 2009). This is the reason why improving 
diagnosis and treatment of brain disorders has remained a challenge compared 
to diseases in other parts of body. Enormous effort has been put into developing 
new drugs for CNS disorders but over 90% of drug candidates have proven 
inefficient, mainly because insufficient amount of drug was able to reach extra-
vascular brain parenchyma (Cummings et al. 2015). 
Actively targeted nanodrugs hold a great promise to improve the treatment 
of neurological disorders by precision delivery to disease site in CNS (Saraiva 
et al. 2016). Targeted nanomedicine approach requires excellent targeting 
ligands that would enable to transport adequate amount of cargo to lesion site. 
Phage display can be used for agnostic identification of peptide ligands that 
target receptors in the vascular beds in the CNS (Ghosh et al. 2018). Such 
homing peptides can be readily conjugated to drugs and nanoparticles to im-
prove their biodistribution and activity. Using nanoparticles for the delivery has 
several advantages over the transport of free drugs, such as attachment of 
multiple copies of targeting peptides for enhanced avidity, prevention of the 
degradation of drugs during delivery and controlled release at disease site 
(VanDyke et al. 2016; Hua et al. 2018). 
The thesis summarizes our work on identification and characterization of 
brain targeting peptides that could be used to improve the diagnosis and treat-
ment of various neurological disorders. To enhance the validation process of 
homing peptides and to select the best performing peptides, an ultrasensitive 
quantification system based on isotopic silver nanoparticles and ICP-MS 
analysis was developed. Phage display on Alzheimer`s disease (AD) model was 
used to identify new peptides to target vascular changes in AD and studied 
suitability of a previously identified targeting peptide for malignant glioma 
nanodrug delivery. 
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2. LITERATURE REVIEW 
2.1. Drug delivery challenge 
Drug concentration at the biological receptor site determines the magnitude of 
the pharmacological response (Campbell and Cohall 2017). Even the agents 
with excellent bioavailability, long plasma half-lives and favorable receptor 
binding properties do not pass clinical testing if not able to reach the target at 
required concentration. Therefore, efforts to develop more efficacious drugs 
focus increasingly on optimizing drug biodistribution in tissues, cells, and on 
subcellular level. Encapsulating drugs into nanoparticles (NPs) can overcome 
some of the limitations of conventional medicine by promoting more desirable 
pharmacokinetics and biodistribution (Ventola 2017). The encapsulation in NPs 
can increase drug concentration at the intended site(s) of action (Vieira and 
Gamarra 2016). Loading a drug in nanocarriers can increase its stability, pro-
long the circulation time, extend the release of drug, and finally, decrease 
immunogenicity and systemic toxicity (Bobo et al. 2016).  
NPs target tissues passively by taking advantage of longer circulation half-
life and/or actively by using affinity ligands that bind to specific receptors 
expressed in a target tissue (Bertrand et al. 2014). Passive targeting to solid 
tumors relies on leaky vessels and poor lymphatic drainage that result in the 
extravasation and accumulation of drug in the tumor tissue (Maeda, Nakamura, 
and Fang 2013). Coating targeting ligands on NPs enables to fully exploit their 
potential as delivery vehicles. Active targeting improves accumulation of nano-
therapeutics in target tissue and their uptake in target cells, leading to increased 
therapeutic efficacy and reduced off-target side effects (Danhier 2016; Ruos-
lahti 2012). By increasing the local drug concentration, active targeting helps to 
lower the risk of developing drug resistance (Andrieu et al. 2019).  
The first nanodrug on the clinical market – Doxil (PEGylated liposomal 
doxorubicin) was approved by Food and Drug Administration (FDA) of the 
United States in 1995 for the treatment of Kaposi’s sarcoma (Barenholz 2012; 
Harris et al. 2002). Compared with free doxorubicin, Doxil had fewer side 
effects. Approved nanodrugs are based on existing drugs that have been nano-
formulated to improve their biodistribution or pharmacodynamic properties. 
Nanoparticle-based therapeutics have been approved for a variety of patho-
logies: cancer, hepatitis, multiple sclerosis, chronic kidney disease, macular 
degeneration, and hemophilia. All clinically approved nanoparticles are non-
targeted passive drug delivery vehicles (Bobo et al. 2016).  
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2.1.1. Vascular heterogeneity and its targeting with  
affinity ligands 
Blood and lymphatic vessels are morphologically, molecularly and physio-
logically diverse and specialized according to the site and physiological status 
of the tissue that they supply (Potente and Mäkinen 2017). In blood vessels, the 
luminal side of the vessels is covered by a single layer of endothelial cells 
(ECs), which form a continuous monolayer in arteries and veins, but can be 
fenestrated or discontinuous in capillaries. Endothelial layer permeability in the 
vasculature in different organs is not uniform. In the brain, ECs in conjunction 
with the supporting cells establish a highly selective blood-brain barrier with 
very low baseline permeability, whereas in the kidney glomerular endothelial 
cells enable rapid filtering of water and unbound drug molecules of less than  
20 kDa. Above mentioned water and unbound drug molecules of less than  
20 kDa are filtered through the glomerulus with the primary urine. Depending 
on tissue and its physiological status, endothelial cells also vary in their ability 
to mediate transport of nutrients and in expression of membrane receptors and 
transporters (Aird 2012). For example, neuronal cells need high levels of 
glucose and the ECs in the brain overexpress GLUT1 that transports glucose 
from blood to the brain parenchyma (Zhao et al. 2015). The ECs in the heart 
express high levels of the fatty acid transporter CD36, because cardiac muscles 
rely on fatty acid catabolism for ATP synthesis (Coppiello et al. 2015). 
Molecular heterogeneity of vascular endothelium has led to the identification of 
tissue and organ specific ligands that could be used for active targeting of drugs 
and nanoparticles into these tissues (Teesalu, Sugahara, and Ruoslahti 2012).  
Normal vascular morphology, permeability, and gene expression are altered 
by many diseases, such as cancer, neurodegenerative disorders, cardiovascular 
disorders, and diabetes. Solid tumors depend on formation of new blood vessels 
to supply malignant tissue with nutrients and oxygen, leading to development of 
disorganized “leaky” vessels. Tumor neovasculature has molecular expression 
pattern different from the normal vessels in the same tissue; several molecular 
markers, like VEGF, integrins, and CD105, are upregulated on angiogenic 
vessels (Chen and Cai 2014). Alzheimer’s lesions express elevated levels of 
RAGE receptor and decreased amount of LRP1 in their brain capillaries. 
Changes in RAGE and LRP1 expression promote disease progression by trig-
gering accumulation of Aβ peptide and compromised BBB (Saraiva et al. 2016). 
Molecular heterogeneity of blood vessels in normal tissues and elevated 
expression of systemically accessible molecular markers at disease sites allow 
affinity-based targeting to enhance drug concentration at disease-site, at the 
same time attenuating off-target side-effects (Ruoslahti 2004).  
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2.1.2. Classes of affinity ligands 
A variety of molecules, such as antibodies, peptides, aptamers, vitamins and 
other low molecular weight compounds, can be used as affinity ligands (Liu et 
al. 2017).  
Antibodies and antibody fragments are widely used as targeting ligands be-
cause of their high affinity and specificity. Several targeting antibodies have 
been approved by FDA for the delivery of radionuclides (e.g. Zevalin or 
Bexxar, anti-CD20 antibodies loaded with 90Y or 131I) and cytotoxic drugs (e.g. 
Trastuzumab emtasine) (Liu et al. 2017). However, most of the monoclonal 
antibodies (mAbs) penetrate poorly into tumor tissue because they are too big to 
extravasate and efficiently diffuse into tissue (Kue et al. 2016). Antibodies with 
high affinity to, e.g. tumor antigens, will stably bind to the first encountered 
antigen; this effect is called “binding site barrier”, it will lead to uneven distri-
bution inside the tumor tissue and suboptimal therapeutic effect. Thus, anti-
bodies with moderate affinity are more favorable to be used as targeting ligands 
(Adams et al. 2001). The use of antibodies have several disadvantages; slow 
clearance of mAbs results in high normal tissue exposure, the Fc region of 
antibodies binds to reticuloendothelial system and can cause toxicities to liver, 
spleen and bone marrow (Liu et al. 2017). Their size makes large scale 
manufacturing process difficult and expensive (Liu et al. 2017). Antibody frag-
ments can offer several advantages over the use of full-length mAbs; due to 
their smaller size antibody fragments can more effectively penetrate into tissues 
and access challenging epitopes and have potentially reduced immunogenicity 
(Bates and Power 2019). 
Peptides are efficient alternative targeting ligands for selective delivery of 
drugs and nanoparticles. Several peptide hormones have already been used for 
tumor targeting, e.g. octreotide, an octapeptide that mimics natural somatostatin, 
has been used to target neuroendocrine tumor (Lopci et al. 2008). The size of 
targeting peptides falls in between the size of small molecule ligands and anti-
bodies. Due to their larger size, they possess much higher binding affinity and 
specificity than small molecule ligands, but still being small enough to possess 
increased diffusion and tissue penetration (Jiang et al. 2019). The major 
problem of peptide ligands is their poor stability. Several modifications such as, 
cyclization, backbone/side chain modification, and unnatural residue substitu-
tion can be used to improve peptide stability against proteolysis (Chen et al. 
2017). Peptide ligands are typically non-immunogenic, and the multivalent pre-
sentation on a NP provides high avidity for the target (Ruoslahti 2012). In addi-
tion, they can be readily conjugated to different drugs, nanoparticles, or radio-
nuclides. Peptides can be synthesized on large scale at low cost (Zhao et al. 
2007). 
Aptamers are nucleic acid macromolecules with high affinity and specificity 
to their targets (Alshaer, Hillaireau, and Fattal 2018). DNA and RNA aptamers 
have been selected against different targets –small molecules, membrane 
receptors and whole living cells (Pereira et al. 2018). Aptamers can be readily 
15 
conjugated to drugs and nanoparticles and their chemical properties provide 
good solubility with low toxicity and immunogenicity. Additional advantage of 
aptamers is low cost of production. The main disadvantage of aptamers is 
sensitivity to degradation by nucleases and rapid clearance from the circulation 
(Alshaer, Hillaireau, and Fattal 2018). Additionally, aptamer-target interactions 
are strongly influenced by slight changes in the microenvironment that can alter 
the secondary and tertiary conformation of aptamers (Jiang et al. 2019). 
Low molecular weight affinity ligands extravasate easily and quickly reach 
their target in vivo. Furthermore, small molecules are rapidly cleared from the 
circulation, if they fail to reach target cells, reducing the possibility of off-site 
toxicity (Srinivasarao and Low 2017; Vlashi et al. 2009). However, limited 
binding interfaces between low molecular compounds and their receptors 
restrict specificity of interaction (Jiang et al 2019). Small molecule ligands are 
amenable to chemical synthesis, making their production cost-effective (Kue et 
al. 2016). Some of the most promising small molecule ligands that have been 
used for tumor targeting are folate derivatives, glutamic acid urea derivatives, 
and low molecular weight analogues of peptide hormone somatostatin (Casi and 
Neri 2015). 
 
 
2.1.3. Agnostic exploration of vascular heterogeneity by  
peptide phage display 
Receptor-specific targeting peptides can be identified using various approaches: 
by using receptor’s native ligands or their analogues (such as folic acid against 
folate receptor (Cheng et al. 2013)); by computer aided design based on the 
structure of the receptor (Chen et al. 2018); or by screening combinatorial 
libraries, such as OBOC combinatorial peptide library (Lam et al. 1991), 
peptide microarray (Xu and Lam 2003), phage-display peptide library (Krumpe 
et al. 2006), and other biological-display peptide libraries (Liu et al. 2017). 
Phage display is a powerful method that can be used to identify peptide ligands 
against simple and complex targets, including proteins, cells, and tissues. 
Phages are bacterial viruses that can be genetically engineered to express 
foreign peptides as fusions to the coat protein. Peptide phage library consist of a 
large number (typically about a billion) of bacteriophages, displaying different 
peptides on its surface (Smith and Petrenko 1997). Selection of phages that bind 
to specific target, “biopanning”, can be performed in vitro, ex vivo and in vivo 
(Liu et al. 2017). Sequential biopanning rounds enrich the library with target-
binding peptides, whereas the background phages are eliminated (Fig. 2). In 
vivo phage display can be used to identify peptides that target systemically 
accessible receptors that can be reached from the vasculature. 
16 
  
 
Figure 1: The schematic representation of (A) M13 phage and (B) T7 phage. 
Adapted from Tan et al. (2016). 
 
 
Numerous bacteriophage species have been employed in phage display systems, 
including f1, fd, T4, M13 and T7 (Deng et al. 2018).  
T7 is a lytic coliphage with double‑stranded DNA, which exhibits increased 
stability and low mutation rate during replication (Deng et al. 2018). Compared 
to filamentous phage-based systems, the peptide libraries constructed with the 
T7 display system retain fewer amino acid biases and have increased diversity 
of displayed peptides (Krumpe et al. 2006). Importantly, the size (~60 nm dia-
meter) and shape of T7 particles and density of displayed peptides are similar to 
what is typically seen for (pre)clinical nanoparticles (Fig. 1b). Density of C-
terminally exposed foreign peptides on T7 particle can be modulated across a 
wide range (1–415 peptides/particle) by amplifying peptide-phages in E. coli 
strains with different expression of wild-type p10 coat protein (T7Select® 
System Manual). As peptide density on phage particle is similar to the density 
on nanoparticles, it means that the novel peptides discovered using T7 display 
system are suitable for multivalent use on the nanoparticles. Multivalent pre-
sentation of peptides on biological phage particles and synthetic nanoparticles 
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increases the avidity and ensures strong target binding even with relatively low 
affinity (Ruoslahti 2012).  
 
 
 
 
Figure 2: In vivo phage display for brain homing peptides. Peptide phage library is 
injected into blood circulation. After 10–60 min circulation, the brain and other organs 
are collected and homogenized in a buffered non-ionic detergent solution. The bound 
phage pool from the brain is amplified and used as input in the next biopanning round. 
After several rounds of selection, phages are recovered from brains and the peptide-
encoding portion of the phage genome is sequenced. Enriched peptides are identified 
and validated further in individual phage homing assays and as synthetic peptides 
labeled with fluorophores or coated on nanoparticles. 
 
 
The M13 phage is another widely used phage-display system with high capacity 
for replication and nonessential regions that allow exogenous gene insertions 
(Liu et al. 2017). M13 phage is a filamentous phage containing single‑stranded 
DNA. M13 phage particles (Fig. 1a) are 6.5 nm in diameter and 1μm in length, 
and the peptides are displayed at one end of the phage particle (Tan et al. 2016). 
The use of filamentous phage systems have several disadvantages compared to 
lytic phage, filamentous phage vectors are associated with a limited cloning 
capacity, which in the case of M13 is < 1500 bp, and their genome exhibits 
markedly reduced stability following insertion of foreign DNA (Deng et al. 
2018). Filamentous phage morphogenesis: phage assembly, secretion, and in-
fection processes, limits significantly the diversity of peptides propagated in the 
M13 libraries as displayed peptides need to be compatible with E.coli secretory 
system (Krumpe et al. 2006). 
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2.1.4. Drug delivery to the brain. Blood-brain barrier 
Already in the 1880s Paul Ehrlich observed that intravenously injected hydro-
philic dyes stain all organs except the brain and the spinal cord (Dyrna 2013). It 
has become well established that the central nervous system has evolved diffe-
rent barriers that are important for protecting it from foreign substances and to 
maintain homeostasis. These protective structures include blood-brain barrier 
(BBB), blood-cerebrospinal fluid (CSF) barrier, blood-spinal cord barrier and 
blood-retinal barrier. The most selective of these barriers is the blood-brain 
barrier (Cipolla 2009). The BBB is crucial for protecting brain cells against 
circulating toxic or infectious agents and preserving the CNS homeostasis 
(Hawkins and Davis 2005). The BBB is impermeable to all large molecules and 
>95% of small molecules. Only a few molecules with specific characteristics 
are able to cross the barrier, such as water, some gases, and some lipophilic 
compounds (Saraiva et al. 2016). Small-molecule drugs need to have molecular 
mass under a 400- to 500-Da threshold, and high lipid solubility to cross the 
BBB in pharmacologically significant amounts (Pardridge 2003). Most low 
molecular weight drugs, mAbs, recombinant proteins, or gene therapeutics, do 
not cross the BBB (Pardridge 2005). 
For most CNS diseases there are candidate drugs that show efficacy in vitro 
and when directly injected in the brain, however these compounds do not cross 
the BBB and are not effective upon systemic administration. For example, cata-
lase could be potentially used to treat patients with chronic neurodegenerative 
diseases, as this enzyme binds to amyloid-β plaques and is a potent antioxidant 
able to fight oxidative stress seen at chronic inflammation (Singhal et al. 2013). 
However, inability of catalase to cross the BBB (and some other features such 
as a short half-life and poor cellular uptake) are not compatible with its 
therapeutic use (Jaffer et al. 2011). Curcumin, a polyphenol derived from 
turmeric herb, has a high affinity for the Aβ peptides and promotes the dis-
aggregation of amyloid-β plaques. However, low bioavailability of curcumin 
excludes its uses for diagnosis and treatment of AD (Tang, Taghibiglou, and 
Liu 2017). Therapeutic hypothermia induced by neurotensin peptide has a 
neuroprotective effect and thereby could improve neurological outcome at 
severe liver failure, stroke, or neonatal ischemia. However, the clinical use of 
neurotensin is hampered because the peptide is not able to cross the BBB and 
enter the CNS to reach its target neurons in the lateral hypothalamus (Tang and 
Yenari 2010). 
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2.1.4.1. Anatomy and physiology of the BBB 
Structurally, the BBB is composed of endothelial cells, astrocytes, pericytes and 
neurons (Fig. 3). Polarized endothelial cells lining the lumen of the cerebral 
capillaries are connected by tight junctions that form selective interface between 
blood and brain (Hawkins and Davis 2005).  
 
 
 
Figure 3: Structure of the BBB and the blood-CSF barrier. (Left) BBB is a highly 
selective barrier that separates blood from the brain parenchyma. BBB is composed of 
network of astrocytes, pericytes, neurons, and endothelial cells. (Right) The blood-CSF 
barrier is a more permissive barrier found in the choroid plexus of each ventricle of the 
brain. The blood-CSF barrier is composed of epithelium-like ependymal cells covering 
fenestrated capillaries. Tight junctions between ependymal cells are leakier to small 
molecules compared to the tight junctions forming the BBB. Adapted from D’Agata et 
al. (2018). 
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Figure 4: Pathways of transport across the BBB. Adapted from Gabathuler (2010). 
 
 
Brain capillary endothelial cells express active transport mechanisms that en-
sure the transport of nutrients into the CNS and exclusion of blood-borne mole-
cules (Fig. 4) (Engelhardt and Sorokin 2009). Small hydrophilic molecules that 
are essential for the brain cells to function, like amino acids and glucose, use 
transporters at the luminal and basolateral side of the endothelial cells. Larger 
and/or hydrophilic molecules such as hormones, transferrin and lipoproteins use 
specific receptors expressed in high numbers on the luminal side of the endo-
thelial cells. These receptors facilitate endocytosis and transcytosis of com-
pounds across the barrier. Small lipophilic molecules are able to diffuse passi-
vely across the BBB but are exposed to efflux pumps such as P-glycoprotein 
and Multidrug Resistance Proteins (Gabathuler 2010). 
Some regions of the brain require a more permissive barrier for proper func-
tioning, such as ventricular and circumventricular areas of the brain. Ventricular 
system is comprised of two lateral ventricles, and a third and fourth ventricle. 
Cerebrospinal fluid (CSF) is produced in the third and fourth ventricles by the 
choroid plexuses and capillaries. CSF protects the brain and spinal cord and 
provides them with important nutrients. Structurally, the choroid plexus is com-
posed of capillaries covered by epithelium-like ependymal cells. Capillaries of 
the choroid plexus are fenestrated and allow direct passage from blood to the 
brain parenchyma. Tight junctions of the ependymal cells that cover the capil-
laries form the blood-CSF barrier (Fig. 3). Tight junctions between the 
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ependymal cells are leakier than between the cells of BBB (Cipolla 2009; 
Saraiva et al. 2016). Transport of compounds from blood into the CSF is similar 
to that into brain, with many of the transporters shared between the tissues. Due 
to the different properties of the two barriers, some compounds predominantly 
enter the brain by crossing the BBB, such as O2, CO2, glucose and amino acids, 
but others like Ca-ions and several hormones have choroid plexus as the major 
site of entry (Laterra et al. 1999). It has been shown that nanoparticles, which 
have been injected intravenously, will accumulate in these leakier areas 
irrespective of their cargo (Xin et al 2012). 
Blood-spinal cord barrier (BSCB) protects and regulates the homeostasis of 
the spinal cord parenchyma. BSCB has similar structure as the BBB: it is 
composed of endothelial cells, basement membrane, pericytes, and astrocytic 
end-feet processes. However, the BSCB has several functional and morpho-
logical differences when compared to the BBB. The microvessels in the spinal 
cord contain glycogen deposits not present in brain capillaries. Compared to the 
BBB, the BSCB is more permeable to variable tracers and cytokines (Pan, 
Banks, and Kastin 1997), potentially due to low expression of tight junction and 
adherens junction proteins in the spinal cord (Bartanusz et al. 2011). 
BBB organization and function are severely altered in brain tumors and at 
neurodegenerative disorders, the disrupted BBB in case of brain tumors is called 
blood-brain tumor barrier (BBTB). BBTB limits the access of anticancer drugs 
to the brain tumor. In low grade diffuse gliomas the tumor cells are present as 
oligocellular aggregates in the brain parenchyma and the BBTB resembles 
structurally and functionally the BBB (Van Tellingen et al. 2015). In contrast, 
high grade gliomas are highly angiogenic tumors with leaky BBTB, as has been 
shown by contrast-enhanced MRI (Dhermain et al. 2010). BBTB shows 
elevated expression of receptors that mediate ligand-dependent drug delivery 
and could be targeted to improve drug delivery to tumor tissue (Ningaraj 2002). 
The BBB is formed by capillaries without fenestrations, but the BBTB can be 
comprised of non-fenestrated capillaries, capillaries with fenestrations and 
capillaries containing inter-endothelial gaps (Schlageter et al. 1999). BBTB 
capillaries present overexpression of drug efflux pumps and multidrug 
resistance-associated proteins, which function against the leaky vasculature and 
prevent the uptake of drugs by cancer cells (Ningaraj 2006). In addition, the 
tumor growth results in increased pressure to the surrounding tissue and leads to 
formation of intracranial edema that also limits the delivery of drugs to tumor 
(Wolburg et al. 2012). 
 
 
2.1.4.2. Affinity targeting of the CNS 
The presence of intact BBB is a major obstacle in treating CNS diseases. As 
less than 2% of the drug candidates are able to penetrate the BBB and to enter 
the cerebral tissue, more efficient CNS delivery strategies are needed to „by-
pass“ the protective BBB shield (Pardridge 2005). The concept of BBB shuttles – 
22 
application of molecular vectors for penetration from systemic circulation into 
brain parenchyma without disrupting the protective barrier – was introduced 
already more than three decades ago (Pardridge 1986). Most commonly used 
CNS delivery approach is receptor-mediated transport that takes advantage of 
highly expressed transport receptors on the luminal side of brain endothelial 
cells, such as transferrin receptor, insulin receptor, low-density lipoprotein 
receptor and LRP1 (Lajoie and Shusta 2014). Over the years, a number of BBB 
shuttle peptides have been published that bind to the receptors and thereby 
allow the transport of different cargoes, including small molecules, nano-
particles and genetic material beyond the BBB (Table 1) (Urich et al. 2015; 
Zarebkohan et al. 2015). Despite the discovery of numerous BBB shuttle 
peptides, crossing the BBB to deliver drugs and diagnostic agents to the brain 
remains still a major hurdle. The shortage of brain selectivity and poor penetra-
tion capacity across the BBB are the two main problems current BBB crossing 
strategies are facing (Ross et al. 2018). Intensive research is ongoing in two 
main directions: firstly, to find new brain-specific markers to improve drug 
transport across the blood-brain barrier and more selectively to diseased cells, in 
order to minimize distribution into normal brain cells (Gao 2016). And 
secondly, to develop new nanocarriers with long plasma circulation that are 
nontoxic, biocompatible, and biodegradable, since the brain has very limited 
capability for elimination and metabolization of the translocated nanoparticles 
(Mi, Cabral, and Kataoka 2019). 
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2.1.5. Brain diseases with unmet drug delivery challenge 
2.1.5.1. Neurological disorders: Alzheimer’s disease 
The frequency of neurological diseases is expected to reach epidemic scale in 
the next decades as the average life expectancy is increasing globally. Neuro-
pathies and neurodegenerative diseases such as Alzheimer’s disease (AD) and 
Parkinson’s disease (PD) lead to adverse health outcomes in patients and put 
immense load on healthcare system (Heemels et al. 2016). Already now, the 
morbidity and mortality caused by brain-related disorders is higher than that of 
cardiovascular diseases and cancer (Sharma et al. 2017). Improved diagnostic 
tools and treatments need to be developed to decrease the burden on affected 
individuals and society (Kevadiya et al. 2018). Current treatments fail to cure 
the neurodegenerative diseases or even slow down their progression and only 
deal with the symptoms (Kevadiya et al. 2018). Treatment with neuroprotective 
agents is likely to be an effective strategy to prevent neuronal degeneration, but 
typically these bioactive compounds are not able to cross the BBB (Levi and 
Brimble 2004). There are clinically approved drugs that have been reported to 
be effective in treating neurodegenerative disorders on experimental models, but 
they lack the ability to cross the BBB or require very high doses causing severe 
off-target side effects. One of the examples is minocycline; it is a broad-
spectrum antibiotic, which has been used over 30 years to treat infections 
caused by Gram-negative and Gram-positive bacteria. Several groups have 
shown it to have neuroprotective effect in various experimental models of CNS 
diseases. Whereas minocycline is able to penetrate the BBB to some degree, it 
must be administered at high doses (with serious side effects) to achieve thera-
peutic concentration in the brain (Sharma et al. 2017). Using targeted delivery 
strategies to transport minocycline and other neuroprotective agents selectively 
to the brain and across the BBB could be the way treat neurodegeneration in 
patients.  
AD is the most common age-related neurological disorder. AD causes wide-
spread neuronal and synaptic loss, amnesia, cognitive impairment, hallucina-
tions, and social deficits. AD is characterized by progressive and irreversible 
damage to neurons (Kevadiya et al. 2018). The most prevalent hypothesis 
regarding AD pathogenesis suggests that the accumulation of β-amyloid peptide 
(Aβ) is the key mechanism causing the disease (de la Torre and Ceña 2018). 
Overproduction of Aβ peptide isoforms causes aggregation of peptide fragments 
into large fibrils that become deposited as insoluble plaques (Golde, Eckman, 
and Younkin 2000). The Aβ plaques form first in the basal cortex but are at 
later stages detected in most neocortical regions except in the hippocampus 
(Braunstein et al. 2016). Aβ plaque toxicity is caused by multiple mechanisms, 
including increased membrane permeability, oxidative stress, synaptic dysfunc-
tion and microglial activation (Lin et al. 2001, Butterfield et al. 2007, Para-
meshwaran et al. 2008).  
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Whereas in most cases the AD begins after the age of 65 years, approximately 
6% of patients have early-onset AD, an autosomal-dominant genetic disease 
that manifests in patients at ages 30–50 (Bateman et al. 2011; Dzamba et al. 
2016). The clinical diagnosis of AD is based on family history, symptoms of 
dementia, imaging by computerized tomography (or magnetic resonance 
imaging), and blood biomarkers (Hane et al. 2017). However, a conclusive AD 
diagnosis can only be obtained post-mortem by autopsy (Kelley et al. 2007). 
Currently, there are only five medications approved for the treatment of AD; 
four cholinesterase inhibitors and N-methyl-D-aspartate receptor antagonist 
(Cummings et al. 2014). These drugs are used to treat cognitive symptoms but 
fail to stop the progression of neuronal damage and loss. Discovery of new 
drugs able to slow down or reverse the progression of the AD is challenging, 
and disappointingly most of the clinical studies using investigational new drugs 
have failed to demonstrate clinical efficacy (Salloway et al. 2014). New cellular 
pathways and molecules involved in AD pathogenesis need to be identified to 
improve diagnosis and treatment. 
 
2.1.5.2. Gliomas 
Malignant glial tumors are the most common primary brain tumors. Gliomas are 
characterized by heterogeneity inside the tumors and between the tumors of 
different patients (Parsons et al. 2008). Gliomas originate from the glial cells: 
astrocytes, oligodendrocytes or ependymal cells. Depending on the cell of origin 
gliomas are classified into 3 groups: astrocytomas (including glioblastomas), 
oligodendrogliomas, and ependymomas; some tumors display a mixed pheno-
type of these different cells (Louis et al. 2016). Glioblastomas (GBM) are the 
most frequent and aggressive of the glial tumors. Despite intense research, 
GBM remains highly malignant with very poor prognosis in the patients. The 
current median survival of the patients is less than 15 months after GBM 
diagnosis (Stupp et al. 2005). GBM treatment combines maximum surgical 
resection of the tumor tissue with the radiation therapy and/or chemotherapy. 
Despite the aggressive treatment, the prognosis remains low due to high 
recurrence rate. Complete resection of the tumor is impossible because of 
anatomical location and highly infiltrative nature of these tumors (Stupp et al. 
2005; Shirahata et al. 2007). Radiation and chemotherapy kill actively pro-
liferating glioma cells but are unable to reach to the quiescent glioma stem cells 
that are hiding in hypoxic regions and behind the blood brain barrier. Recurrent 
GBM that develops from the guerilla cells away from tumor bulk grows rapidly 
and spreads to more distant regions and is more resistant to chemotherapy than 
the initial tumor (Yip et al. 2009).  
Although GBM is highly angiogenic with leaky blood vessels and BBB 
disruption in the core of the tumor, most of the approved anticancer therapeutics 
are not able to cross the BBB or the BBTB (Van Tellingen et al. 2015). 
Currently there are only two anticancer agents, temozolomide and nitrosourea, 
that are able to cross the BBB and reach the cerebral tissue. Neither of these 
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agents is highly effective against GBM and new strategies for GBM manage-
ment are actively sought for with >400 glioblastoma studies ongoing all over 
the world in late 2019 (Argyriou and Kalofonos 2009; clinicaltrials.gov).  
 
 
2.2. Preclinical modeling of glioma and  
neurodegenerative disease 
2.2.1. Glioma modeling in mice 
Tumor modeling in small animals has a crucial role for development of new 
therapeutic strategies, to study tumor biology, and predict efficacy and toxicities 
of potential new therapies. Implantable brain tumor models have been widely 
used and well characterized (Assi et al. 2012).  
Commercially available tumor cell lines are extensively used for both in 
vitro and in vivo research. These cell lines were initially derived from patient 
GBM tumor tissue and are commonly cultivated in 2D in serum-containing 
medium (Kijima and Kanemura 2017). Human-derived glioma cells have to be 
xenografted into immunodeficient animals; transplantation of cancer cells into 
rodents by stereotactic injection enables to induce tumors at specific anatomical 
structures within the brain (Assi et al. 2012). Patient-derived glioma cells 
(PDGCs) give rise to tumors that grow rapidly, have high engraftment rate, and 
good reproducibility (Fig. 5b) (Huszthy et al. 2012). However, xenografts 
induced by PDGCs often fail to reflect important clinical characteristics of real 
patient tumors, as the cell-line derived tumors are often circumscribed and fail 
to exhibit the hallmarks of clinical glioma: the presence of necrotic areas and 
single-cell invasion into surrounding brain tissue (Mahesparan et al. 2003).  
Patient-derived xenografts (PDX) are established by implanting fresh tumor 
tissue or cultured tumor spheroids into immunodeficient animals (Fig. 5b) 
(Bjerkvig et al. 1990; Tentler et al. 2012). PDX models are maintained by serial 
passaging in animals or by producing tumor spheroids, often under serum-free 
neurosphere-culture conditions (Bjerkvig et al. 1990). PDX models are widely 
used in translational research, as they preserve both the genetic and histological 
features of parental tumors. Array-comparative genomic hybridization analysis 
has shown that in contrast to cell line xenografts, which genetically do not 
resemble patient tumors, PDX spheroids retain the genetic profile of parental 
tumors even after multiple in vitro/in vivo passages. Importantly, the PDX 
tumors maintain tumor heterogeneity; they remain infiltrative and have necrotic 
areas, which are main characteristics of clinical GBM (De Witt Hamer et al. 
2008). However, not all human gliomas are tumorigenic when injected to 
animals; and some tumors fail to produce tumor spheroids. The time needed to 
establish the tumor varies between passages and different PDX tumors, making 
experimental planning challenging (Huszthy et al. 2012). Despite the dis-
advantages, PDX models are the way to move towards personalized treatment 
of tumors (Kijima and Kanemura 2017). 
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Figure 5: In vivo GBM modeling. (A) Genetically engineered mouse models are 
generated using Tet-regulation or Cre-inducible gene alleles. These GBM models are 
molecularly highly defined but fail to reflect biological heterogeneity seen in human 
GBM. (B) Patient-derived glioma cells (PDGCs) give rise to tumors that grow rapidly, 
have high engraftment rate, and good reproducibility. Tumors derived from PDGCs are 
often circumscribed without the presence of necrotic areas and single-cell invasion into 
surrounding tissue. Patient-derived xenografts (PDX) are generated by implanting fresh 
tumor tissue or cultured tumor spheroids into immunocompromised animals. Ideally, 
PDX models preserve both the genetic and histological features of parental tumors; 
florid microvascular proliferation (lower right panel) and diffuse infiltrative growth in 
the white matter (upper right image). Of note, as illustrated by a xenograft derived from 
U87 cells (lower left panel), PDGC models often fail to show diffuse infiltration in 
brain parenchyma. Adapted from Lenting et al. (2017).  
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Genetically engineered mouse models (GEMMs) resemble the histopathology 
and molecular features of human tumors (Fig. 5a). In genetically engineered 
models, gene expression has been manipulated often by using Tet-regulation or 
Cre-inducible gene alleles. GEMMs are especially useful to verify genetic 
alterations which are important for tumor initiation and progression (Kijima and 
Kanemura 2017). A disadvantage is that as the GEMM tumors are formed by 
cells with specific genetic changes, the tumors do not exhibit the biological 
heterogeneity seen in clinical GBM (Lenting et al. 2017).  
 
 
2.2.2. Preclinical modeling of neurodegenerative diseases 
To better understand AD pathology and progression, several human amyloid 
precursor protein (APP) transgenic models have been developed, these mouse 
lines express various mutations identified from patients with familial AD 
(Saraiva et al. 2016). hAPP-J20 model overexpresses human APP with Swedish 
mutation (K670N/ M671L) and Indiana mutation (V717F); Tg2576 model 
expresses human APP with the Swedish mutation (K670N/ M671L) 
(www.alzforum.org/research-models/j20-pdgf-appswind; Van Dam and De 
Deyn 2011). As these models rely on mutations from familial forms of human 
AD (5% of AD cases), they fail to replicate the complete neuropathology 
spectrum seen in patients. Nevertheless, AD animal models are crucial for 
developing new therapeutic strategies (Saraiva et al. 2016).  
PD models are based on the administration of toxins that cause selective 
death of dopaminergic neurons (Saraiva et al. 2016). Two of the most promising 
models are the rotenone model and the combined paraquat/maneb model. 
Rotenone and paraquat are pesticides; maneb is a fungicide that has been linked 
to the development of parkinsonian symptoms in humans (Schapira and Jenner 
2011; Thiruchelvam et al. 2000). PD neurotoxic models are essential for under-
standing consequences of striatal dopamine loss and enable to develop current 
dopaminergic therapies (Bové et al. 2005; Schapira and Jenner 2011). Nume-
rous genetic PD models have been developed using transgenes with mutations 
causing familial PD. Genetic models are mainly used for modeling familial PD 
but can also be used to study more common PD mechanisms. None of the 
current models recapitulates the complex and progressive pathology of human 
disease (Jagmag et al. 2016).  
 
 
2.3. Nanomedicine 
The use of nanoparticles has a surprisingly long history; already during Roman 
times gold nanoparticles were used by artisans to stain glass (Giljohann et al. 
2010). The idea of using nanoparticles for medical purposes dates back more 
than a century ago, when German scientist Paul Ehrlich formulated a concept of 
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targeted delivery of drugs, that he called Zauberkugeln or magic bullets 
(Kreuter 2007). 
Even today the nanomedicine is seen as the “the magic bullet” that could 
improve cancer therapy and ameliorate treatment of neurological disorders by 
developing noninvasive therapies that are more effective in reaching the target 
sites, have increased therapeutic efficacy, and cause less adverse side-effects 
(VanDyke et al. 2016; Hua et al. 2018). Multitude of nanoformulations of 
different composition, size, shape, and surface properties, have been designed 
for therapeutic, diagnostic and theranostic applications (Fig. 6), but only few of 
them have been approved for clinical use (Danhier 2016; Hua et al. 2018; L. 
Zhang et al. 2008).  
 
 
 
Figure 6: Design, physicochemical properties and biomedical applications of 
targeted nanoparticles. Adapted from Kevadiya et al. (2018). 
 
 
2.3.1. Nanoparticle characteristics  
The half-life of nanoparticles in the systemic circulation and how well they are 
able to accumulate in the target tissue is determined by their physicochemical 
properties. Very small particles, <5 nm, are not suitable for drug delivery, as 
they will be cleared quickly from the blood by kidneys and particles > 200 nm 
accumulate in the liver and spleen (Blanco, Shen, and Ferrari 2015; Ernsting et 
al. 2013). Nanoparticles with size between 8 nm and 100 nm are considered 
optimal for tumor targeting, as the circulation time is prolonged and they are 
still small enough to escape from the leaky vasculature present in tumors 
(Albanese, Tang, and Chan 2012). Bigger nanoparticles have longer half-life, 
but they would not be able to go through the fenestrations on the angiogenic 
blood vessels (Yue et al. 2013). Inside the tumor tissue, the correlation between 
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nanoparticle size and the penetration is reversed, with smaller nanoparticles able 
to accumulate deeper inside the tumor parenchyma, and bigger particles 
remaining close to the vasculature (Albanese, Tang, and Chan 2012). To take 
the advantage of the both phenomena, size-switchable nanoparticle systems 
have been developed that exploit the advantage of the longer circulation of 
larger particles and after extravasation particles shrink due to low pH or 
enzymatic cleavage, to penetrate more effectively (Ruan et al. 2015; Zhang et 
al. 2016).  
The shape of nanoparticles has a strong effect on their distribution in the 
body and uptake by cells. Spherical nanoparticles are most often used in the 
preclinical studies, as it is relatively easy to synthesize them, but it has been 
shown that elongated nanoparticles have prolonged circulation and extravasate 
more effectively through the pores in tumor vessels (Geng et al. 2007; 
Stylianopoulos and Jain 2015). Targeted elongated particles have also stronger 
adsorption to their receptors; it has been shown that rod shape particles coated 
with transferrin receptor had seven times higher accumulation in the brain 
compared to spherical nanoparticles with the same targeting ligand (Kolhar et 
al. 2013).  
The surface of nanoparticles is often coated with polyethylene glycol (PEG) 
to protect the particles from formation of protein corona, which would lead to 
aggregation and quick blood clearance by reticuloendothelial system (Jokerst et 
al. 2011). PEG is a water-soluble polymer that forms brush-like structure 
covering the particles. PEG has high hydration that enables to form water cloud 
around the particles protecting them from interactions with neighboring NPs, or 
with the plasma proteins. Nanoparticles with PEG coating have close to neutral 
surface charge independent of the molecules that have been PEGylated (Suk et 
al. 2016). Circulation time and delivery efficiency of the nanoparticles is 
strongly influenced by their zeta potential. Particles with neutral zeta potential 
have higher delivery efficiency compared to particles with negative or positive 
zeta potential (Wilhelm et al. 2016). Moreover, it has been shown that NPs with 
high zeta potential > 45 mV can damage the blood-brain barrier, and particles 
with low zeta potential are rapidly opsonized and cleared by macrophages 
(Honary and Zahir 2013; Lockman et al. 2004). 
 
 
2.3.2. Silver nanoparticles 
Silver nanoparticles (AgNPs) are used for various applications, including as 
antibacterial agents in medical device coatings, cosmetics, textiles and health-
care products (Sukhanova et al. 2018). These nanosized metallic particles can 
possess very diverse physical, chemical and biological properties depending on 
their surface-to-volume ratio, shape, and surface chemistry, making them useful 
for various bio-applications such as antibacterial, antifungal, antiviral and anti-
inflammatory agents (Zhang et al. 2016). The broad use of AgNPs has caused 
concerns regarding the possible risks for the human health and the environment. 
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Several studies have shown that the AgNPs are toxic by causing direct damage 
to cell membranes, by generation of active oxygen species, and by release Ag+ 
ions (Sukhanova et al. 2018). Majority of these toxicity studies have been 
conducted using uncoated silver particles that can be oxidized and are able to 
release the ions. Coating the AgNPs with sodium citrate, polyvinylpyrrolidone, 
or polyethylene glycol molecules decreases their toxicity (Fahmy et al. 2019) . 
AgNPs are well-suited for preclinical studies as the model payloads because 
these particles can be easily functionalized with targeting peptides and 
fluorescent dyes. AgNPs with surface-bound fluorophore have intense signals 
as the nanoparticles increase the fluorescence intensity of the dye by about an 
order of magnitude due to plasmonic enhancement. By using silver bio-
compatible etchant to dissolve exposed AgNPs, it is possible to distinguish 
internalized particles from unbound and cell surface bound particles, allowing 
to study the cellular uptake of AgNPs (Braun et al. 2014).  
 
 
2.3.3. Iron oxide nanoworms 
Iron oxide nanoparticles are extensively used due to their magnetic properties 
that enables to exploit them for magnetic hyperthermia, magnetic separation and 
as contrast agent for MR imaging (Korchinski et al. 2015). As iron oxide NPs 
are reactive with oxidizing agents, the particles are usually coated with hydro-
philic compounds (e.g. dextran) that do not affect the magnetic properties. 
Coated iron NPs are nontoxic and biocompatible and show prolonged systemic 
circulation (Ali et al. 2016). Dextran-coated ultrasmall superparamagnetic iron 
oxide ferumoxtran-10 nanoparticles used for MRI, have plasma half-life in 
humans up to 30 h (Arami et al. 2015). 
Iron oxide nanoworms (IONWs) are approximately 100 nm strings of iron 
cores that are PEGylated and coated with dextran (Park et al. 2009). The 
elongated shape of IONWs extends their half-life in blood circulation and 
provides enhanced interaction between targeting ligands and their receptors. 
IONWs can be used for theranostic purposes, as their surface can be readily 
coated with targeting ligands and drugs, and their magnetic core is compatible 
with MR imaging (Park et al. 2009; Ruoslahti 2017). Peptide targeted cytotoxic 
IONWs loaded with proapoptotic peptide D[KLAKLAK]2 have been previously 
used to treat glioblastoma in orthotopic mouse models (Agemy et al. 2013). 
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2.4. Summary of the literature 
Many people all over the world are diagnosed with age-related brain disorders, 
and as overall life expectancy is in rise, even more people will be affected by 
these pathologies. The drugs currently available for the treatment of AD and 
other neurodegenerative disorders do not slow down the progression of the 
diseases or cure the patients. Instead, they only temporarily alleviate the symp-
toms of neurodegeneration. To help the patients and to relieve the burden on 
health care system and society, early diagnosis methods and more efficient 
treatments need to be developed.  
Treatment of CNS disorders is hampered by the presence of BBB – a highly 
selective protective barrier impermeable to most potential neuropharma-
ceuticals. Despite intense research the progress in development of new therapies 
for neurodegenerative disorders and brain tumors has been excruciatingly slow, 
mainly because large majority of the drug candidates have failed to reach the 
extravascular brain parenchyma. But most likely any effective treatment for 
neurodegenerative disorders would require therapeutic agent to be transported 
across the BBB, thereby the identification of efficient BBB targeting ligands are 
of utmost importance. Precision delivery of nanoscale carriers or drugs may 
allow for effective and site-specific transport of imaging agents, drugs, and 
other bioactive molecules across the BBB, to diagnose and treat brain tumors 
and neurodegenerative disorders. 
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3. AIMS OF THE STUDY 
Brain parenchyma is shielded from systemic circulation by the BBB that allows 
penetration of only a limited number of agents with very specific characteristics. 
One strategy to improve delivery of drugs and nanoparticles across the barrier is 
to use homing peptides that interact with systemically accessible transport 
receptors in the brain. This doctoral thesis focused on the identification and pre-
clinical validation of novel peptides, which could be used to target normal 
central nervous system and different neurological pathologies.  
Validation of homing peptides is of critical importance for peptide develop-
ment to establish whether the targeting takes place and on an adequate level. 
Targeting peptide validation typically involves in vitro and in vivo sample mani-
pulation and is prone to artefacts. To improve the validation of homing peptides 
on cultured cells and in vivo, a highly sensitive and internally controlled AgNP-
based cellular uptake/biodistribution quantification method was developed. This 
new method enables analysis of the tissues and cells with minimal prior sample 
processing. 
 
More specifically the goals were: 
1. Development of nanoparticle quantification system based on isotopically 
tagged AgNPs to study accessible affinity peptide receptors on cells (II) 
2. Development of internally controlled AgNP quantification system for nano-
particle homing studies (I) 
3. Refinement of the AgNP quantification method for in situ analysis of tissues 
(I) 
4. Targeting glioblastoma with nanoparticles functionalized with homing 
peptide (III) 
5. Identification of novel peptides to target AD (IV). 
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4. MATERIALS AND METHODS  
4.1. Peptides 
Peptides (Table 2) were synthesized using Fmoc/t-Bu chemistry on a micro-
wave-assisted automated peptide synthesizer (Liberty, CEM Corporation, NC, 
USA), purified by HPLC using 0.1% TFA in acetonitrile-water mixture to 
90%–95% purity and validated by Q-TOF mass spectral analysis. Fluorescent 
peptides with blocked C-terminus were synthesized in-house by using 5(6)-
carboxyfluorescein (FAM) with 6-aminohexanoic acid spacer attached to the N-
terminus of the peptide, or ordered from a commercial supplier (TAG Copen-
hagen, Denmark).  
 
 
Table 2: Previously identified peptides used in the in vitro and in vivo studies. 
 
Peptide 
sequence 
Identification Target site and 
receptor 
Reference Publica-
tion in 
thesis 
RPARPAR 
Prototypic 
CendR peptide  
Lungs, heart, and 
angiogenic 
vasculature; receptor 
are NRP-1 and NRP-2 
Teesalu et al. 
2009 
I-II 
CGKRK 
In vivo phage 
display on 
epidermal 
carcinogenesis 
mouse model 
Angiogenic blood 
vessels and tumor 
cells; receptors are p32 
and calreticulin 
Hoffman et al. 
2003 
II 
AKRGARSTA 
(LinTT1) 
In vitro phage 
display on 
recombinant 
human p32 
protein 
Tumor lymphatics, 
tumor-associated 
macrophages, tumor 
endothelial cells, and 
tumor cells; receptor is 
p32 
Paasonen et al. 
2016 
III 
CAGALCY 
In vivo phage 
display on 
healthy mice 
Brain microvessels; 
receptor is unknown 
Fan et al. 2007 V 
 
 
4.2. Targeted nanoparticles 
Three different nanoparticle platforms were used in the experiments presented 
in this thesis: AgNPs, IONWs and albumin-paclitaxel NPs (Fig. 7).  
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Ultraviolet-visible (UV-vis) absorption spectrum was analyzed with a Nanodrop 
2000c spectrophotometer (Thermo Scientific Inc., Washington, USA) to quan-
tify molarity of AgNPs. Dynamic Light Scattering (DLS; Zetasizer Nano ZS, 
Malvern Instruments, UK) was used to assess the polydispersity and hydro-
dynamic radius of the particles. Transmission electron microscopy (TEM; Tec-
nai 10, Philips, Netherlands) was used to characterize the morphology of the 
nanoparticles. 
 
4.2.1  Synthesis of nanoparticles 
4.2.1.1. Silver nanoparticles 
Silver nanoparticles (AgNP) with four different compositions were used in the 
experiments: wtAg, Ag107, Ag109 and wtAg-Pd (Table 3). AgNP were synthe-
sized in-house using Lee and Meisel citrate method or its modified version 
(Dadosh 2009; Lee and Meisel 1982). Synthesis of the particles was conducted 
using natural silver (composed of 51.8% Ag107 and 48.2% Ag109 isotopes) in 
case of wtAgNPs and wtAg-Pd, or by using isotopically pure silver (Ag107 or 
Ag109) in case of isotopic AgNPs. WtAg-Pd nanoparticles contained 1% 
naturally occurring Pd that was added in the form of Pd(NO3)2 at the end of 
synthesis process.  
Synthesized particles had the Ag core size in the 20–70 nm range. Nano-
particles were functionalized with NeutrAvidin (NA) for biotinylated-peptide 
conjugation, and with lipoic acid-polyethylene glycol (1k)-NH2 (PEG) mole-
cules (Braun et al 2014). The terminal amines of PEG were used for coupling of 
CF555-N-hydroxysuccinimide-dye (NHS-dye). Nanoparticles with targeting 
ligand were prepared by attaching biotinylated peptides to the particles; in case 
of control particles the biotin binding pocket was blocked with free D-biotin. 
Nanoparticles made of naturally occurring silver were used for optical 
imaging of NP distribution on tissue sections; fluorescence signal of CF555 dye 
was detected by confocal microscopy. Silver enhancement procedure that was 
conducted on tissue sections enabled to visualize silver grains using dark-field 
microscopy. Atomically distinct nanoparticles Ag107, Ag109 and wtAg-Pd 
were used for analysis of cells and tissue homogenates by ICP-MS. Ag107 and 
Ag109 particles were used in homing experiments where silver was quantified 
from tissue lysates by ICP-MS and tissue sections by laser ablation-ICP-MS. 
Extracellular AgNPs can be “etched”, or dissolved, using a mild bio-
compatible solution to differentiate between internalized and surface-bound 
exposed particles (Braun et al 2014). Etching solution was prepared fresh before 
each use from 0.2 M stock solutions of Na2S2O3 and K3Fe(CN)6 stored in the 
dark. A working solution, 10 mM in each component diluted in PBS, was 
applied to cells for five minutes followed by PBS washes. 
.
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4.2.1.2. Iron oxide nanoworms 
NWs were synthesized as previously described (Fogal et al. 2015; Miao et al. 
2014). Briefly, aminated NWs were PEGylated with maleimide-5k-PEG-NHS 
(JenKem Technology, TX, USA). Peptides were coupled to NWs through a 
thioether bond between the thiol group of a cysteine residue added to the N-
terminus of the peptide and the maleimide on the functionalized particles.  
 
 
4.2.1.3. Albumin-paclitaxel nanoparticles 
Albumin-paclitaxel nanoparticles (Abraxane) were purchased from producer 
(Celgene). For peptide coupling, 5 mg of albumin-paclitaxel nanoparticles were 
dissolved in 1 mL of PBS (previously purged with nitrogen) and combined with 
0.3 mg (0.6 µmols) of linker sulfosuccinimidyl 4-(N-maleimidomethyl)cyclo-
hexane-1-carboxylate in 0.2 mL of PBS. The mixture was stirred for 30 min at 
RT and modified albumin-paclitaxel nanoparticles were purified using a NAP-
10 column (GE Healthcare Life Sciences). 0.25 µmol of LinTT1 peptide with 
N-terminal extra cysteine residue dissolved in 0.2 mL of PBS was slowly added 
to the purified albumin-paclitaxel nanoparticles, the mixture was stirred for 1 h 
at RT and purified by gel permeation chromatography using Sepharose 4B 
columns (GE Healthcare Life Sciences).  
 
 
4.2.2. Cell lines 
Nine different tumor cell-lines derived from human or mouse tumors (Table 4) 
were used in the experiments. PPC-1 cells were obtained from the Ruoslahti 
laboratory at Sanford-Burnham-Prebys Medical Discovery Institute (SBPMDI), 
and M21 cells were a gift from David Cheresh at University of California San 
Diego (UCSD). U87-MG GBM and U251 cells were acquired from ATCC, and 
NCH421K cells from CLS Cell Lines Service GmbH (Eppelheim, Germany). 
WT-GBM and VEGF-KO GBM cells were a gift from Gabriele Bergers 
(Leuven, Belgium), P13 spheroids were a gift from Rolf Bjerkvig (Bergen, 
Norway), and 005 cells were established from murine GBM as previously 
described in Marumoto et al 2009.  
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4.2.3. In vitro experiments 
4.2.3.1. AgNP binding to immobilized proteins 
His-tagged NRP-1 b1b2 domain (wt and mutant) were expressed and purified as 
described (Teesalu et al. 2009). 6× His-Tagged p32 was expressed in Rosetta-
gami-2 cells (Novagen). The protein was purified by IMAC using HIS-select 
resin (Sigma) with an imidizole gradient from 20–300 mM and eluted fractions 
were analyzed on analytical SDS-PAGE. Sedimentation velocity assay was 
used to confirm the trimeric state of the recombinant p32 protein. AgNP binding 
experiments to magnetic beads coated with recombinant proteins were carried 
out with wtAgNPs. Ni-NTA magnetic agarose beads (Qiagen) in Tris buffer  
(50 mM Tris pH 7.4, 150 mM NaCl, 0.05% NP40, 5 mM imidazole) were 
loaded, as suggested by the manufacturer, with either the b1b2 binding domain 
of NRP-1, with p32, or with a b1b2 mutant, followed by multiple washes. NPs 
were incubated for one hour with the protein-loaded beads in Tris buffer with 
1% BSA at room temperature with gentle agitation, followed by washes, and 
elution with high imidazole concentration buffer (PBS, 400 mM imidazole,  
150 mM NaCl, 1% BSA, 0.05% NP40). The eluted samples were analyzed by 
UV-vis spectrophotometer (NanoDrop 2000c, Thermo Scientific). The spectrum 
and maximum absorbance at 400 nm were recorded for each sample. 
 
 
4.2.3.2. Receptor-dependent binding and uptake of AgNPs 
Receptor-dependent binding of AgNPs by two cancer cell-lines, M21 and PPC-
1, was assessed by flow cytometry and uptake of AgNPs was determined by 
confocal microscopy. Both are well studied cell-lines with known receptors 
(Sugahara et al. 2009; Teesalu et al. 2009). PPC-1 cells express high levels of 
Table 4: Cell-lines used in the in vitro and in vivo experiments. 
 
Cell-line Application Publication  
in thesis 
PPC1 Human prostate 
adenocarcinoma 
In vitro II 
M21 Human melanoma In vitro II 
U87-MG Human glioblastoma In vitro and in vivo III 
WT-GBM Mouse glioblastoma In vitro and in vivo III 
VEGF-KO-GBM Mouse glioblastoma In vitro and in vivo III 
005 Mouse glioblastoma In vivo III 
NCH421k Human glioblastoma In vitro and in vivo III 
U251 Human glioblastoma In vitro IV 
P13 Human glioblastoma In vivo IV 
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NRP-1, whereas M21 cells lack the extracellular NRP-1 expression (Teesalu et 
al. 2009). Both cell lines have p32 protein exposed at the cell surface. 
To study cellular uptake, three different types of wtAgNPs were prepared by 
conjugating biotinylated peptides: biotin-X-RPARPAR or biotin-X-SGKRK-
NH2, or by blocking the biotin binding pocket with free biotin. M21 and PPC1 
cells were cultured in DMEM high glucose medium containing 100 IU/mL of 
penicillin, streptomycin, and 10% of fetal bovine serum (GE Healthcare, UK) in 
5% CO2 atmosphere.  
For fluorescence confocal imaging the cells were washed twice with warm 
medium after which fresh medium with AgNP at 0.2 nM was added. The cells 
were incubated with NPs for one hour at 37 °C. After incubation the NP 
containing medium was removed, the cells were washed and fixed with -20 °C 
methanol for 60 sec. The cells were blocked (PBS, 1% BSA, 0.05% Tween-20) 
for 30 min at room temperature and co-stained with NRP-1 and p32 antibodies, 
and DAPI. The cells were imaged using fluorescence confocal microscopy 
(Zeiss LSM 510; Olympus FV1200MPE, Germany). 
For flow cytometry experiments the cells were washed twice with warm 
medium, and fresh medium with AgNP at 0.2 nM was added. The cells were 
incubated with NPs for one hour at 37 °C. After incubation the AgNP con-
taining medium was removed and the cells were washed with PBS. Cells were 
dissociated using Cell Dissociating Buffer (Gibco) and suspended in 300 μl 
PBS. Analysis was done using BD Accuri flow cytometer by monitoring the 
555 channel FL2. 
 
4.2.4. Animal experiments 
Animal experimentation protocols were approved by Committee of Animal 
Experimentation of Estonian Ministry of Agriculture (Permit #48), by the Tel 
Aviv University Institutional Animal Care and Use Committee, and by the 
Institutional Animal Care and Use Committee of Sanford Burnham Prebys 
Medical Discovery Institute.  
Athymic nude mice were purchased from Harlan and Balb/c mice were 
purchased from Charles River. Animal experiments were conducted using 
healthy mice or mouse models of various CNS disorders. Six different glio-
blastoma models (Table 5), two AD models, PD model and acute brain injury 
model were used in the experiments. 
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4.2.4.1. GBM tumor models 
Cell culture reagents were from Gibco (USA) if not stated otherwise. WT-GBM 
and VEGF-KO-GBM cell lines (Blouw et al. 2003) were cultured in MEM with 
Earl’s salts (Capricorn Scientific, Germany) supplemented with 100 IU/mL of 
penicillin/streptomycin, 1% sodium pyruvate, 0.01 M HEPES, 0.6% glucose 
(Applichem, USA) and 5% of fetal bovine serum (GE Healthcare, UK). 
NCH421k cells (Campos et al. 2010) were cultivated in neurobasal medium 
complemented with B27 neurobasal supplement (Thermo Fisher Scientific, 
USA), 100 IU/mL of penicillin/streptomycin, 0.4 mM Glutamax, 20 ng/ml basic 
FGF, 20 ng/ml EGF and 40 µg/ml of heparin (Sigma-Aldrich, USA). U87-MG 
cells were grown in DMEM (Lonza, Belgium) containing 100 IU/mL of 
penicillin, streptomycin, 10% fetal bovine serum, 1% sodium pyruvate and 1% 
non-essential amino acids (Sigma-Aldrich, USA). P13 spheroids (Fack et al. 
2015) were grown in DMEM (Lonza, Belgium) containing 100 IU/mL of 
penicillin/ streptomycin, and 10% of fetal bovine serum (GE Healthcare, UK) as 
3D culture on 0.75% agar coated flasks. All cells were cultured at 37°C in a 
humidified atmosphere containing 5% CO2.  
For induction of orthotopic GBM xenografts in nude mice, 7 × 105 (WT-
GBM, VEGF-KO-GBM), 3 × 105 (NCH421k) cells, 3 × 105 (005) cells or 3 × 105 
(P13) cells from dissociated spheroids were implanted intracranially in the right 
striatum of the brain (coordinates: 2 mm laterally and 2 mm posteriorly from 
bregma and at 2.5 mm depth). For induction of s.c. U87-MG tumors, 4 × 106 cells 
were injected under the skin of the right flank of nude mice. Intracranial tumors 
were allowed to develop for 6–7 (WT-GBM), 12–14 (VEGF-KO-GBM), ~30 
(NCH421k), 10 (005) or ~35 (P13) days before performing experiments. U87-
MG s.c. tumors were allowed to grow until tumors had reached ~ 1 cm3. 
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4.2.4.2. Models of CNS disorders 
Three transgenic mouse models of neurodegenerative disorders were used: AD 
models hApp-J20 and Tg2576, and PD model mTHY-1-α-synuclein. All the 
three transgenic mouse models were derived from C57BL/6 mice. The acute 
brain injury model was set up as previously described in Mann et al. 2016. 
 
 
4.2.4.3. In vivo phage display 
To find AD targeting peptides, CX7C (1e10 pfu) naïve phage library was in-
jected intravenously to hAPP-J20 mice and allowed to circulate for 30 minutes. 
After circulation, the animals were anesthetized with 2.5% avertin and perfused 
intracardially with PBS. Hippocampus and control organs were collected and 
homogenized in LB-NP40 (1%). Bound phages were rescued by amplification 
in E. coli and their genomic DNA was sequenced by Ion Torrent next gene-
ration DNA sequencing system. 
 
 
4.2.4.4. Peptide homing studies 
To study AD peptide homing, mice were intravenously injected with 50 nmoles 
of peptide dissolved in PBS and allowed to circulate for 30 minutes. Mice were 
then anesthetized and perfused with PBS and all major organs were fixed in 4% 
paraformaldehyde at pH 7.4 overnight. The organs were washed with PBS and 
placed in graded sucrose solutions before embedding into optimal cutting tem-
perature (OCT) medium. 10 μm thick sections were prepared by cryosectioning 
and subjected to immunostaining.  
 
 
4.2.4.5. Homing of nanoparticles 
To study homing of AgNPs, four different types of particles were prepared by 
attaching the following biotinylated peptides: biotin-X-RPARPAR-OH; biotin-
X-RPARPAR-NH2; biotin-X-CAGALCY (X = aminohexanoic acid), or by 
blocking the biotin binding pocket with free biotin. AgNPs at O.D.50 were 
suspended in 200 µl of PBS and injected intravenously to Balb/c mice. 1 h or  
5 h after i.v. administration the mice were perfused intracardially with PBS. 
Organs were snap-frozen in liquid N2 for cryosectioning. 
For microscopic imaging, 10 μm cryosections were fixed in 4% para-
formaldehyde in PBS and stained with DAPI. For silver enhancement, cryo-
sections were fixed in MeOH (−20 °C for 60 s), washed in PBS, and treated 
with Silver Enhancement kit (Molecular Probes) for 30–40 min with fresh 
solution added every 13 min. The reaction was stopped in 75 mM Na2S2O3 in 
water. The nuclei of cells were stained with DAPI, followed by dehydration of 
sections through graded ethanol series, xylene, and mounting in DPX mounting 
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medium. The signal in fluorescent confocal images and dark-field microphoto-
graphs was quantified with ImageJ freeware. 
FAM-labeled NWs were injected intravenously (7.5 mg/kg Fe), and 1 or 5 h 
post i.v. administration the animals were perfused with DMEM-1% BSA. The 
organs were collected and snap-frozen in liquid nitrogen for cryosectioning. For 
confocal microscopy, the tissues were sectioned at 10 μm and stained with 
antibodies and DAPI. 
Iron oxide nanoparticles (NWs) conjugated with DAG peptide (DAG-
IONWs) were injected i.v. to 9-month-old hPPP-J20 mice and age-matched WT 
mice. NWs were allowed to circulate for 5 h before perfusion with PBS. The 
organs were collected and snap-frozen in liquid nitrogen for cryosectioning. 
NWs in tissue sections were stained with Prussian blue and the sections were 
counterstained with nuclear fast red.  
 
 
4.2.4.6. ICP-MS experiments 
Inductively coupled plasma mass spectrometry (ICP-MS) allows extremely high 
sensitivity analysis of elements and even enables discriminations of different 
isotopes of the same material (Agilent 2015). Two distinct ICP-mass spectro-
metry methods were applied for ratiometric analysis of cells and organs: ICP-
MS analysis on cells and tissue extracts and laser ablation ICP-MS (LA-ICP-
MS) on frozen tissue sections.  
For ratiometric cell phenotyping, three atomically different AgNPs: Ag107, 
Ag109 and wtAg-Pd, and two different cell lines: M21 and PPC1 cells, were 
used. After incubating cells with AgNPs, the medium was removed, and cells 
were washed to remove the unbound particles. Cells were dissociated using 
non-enzymatic Cell Dissociation Buffer (Gibco), transferred to 1.5 mL tubes 
and disrupted with 2% SDS solution. The samples were analyzed using an 
Agilent 8800 QQQ ICP-MS. 
For ratiometric ICP-MS-based biodistribution experiments, Ag107 and 
Ag109 isotopic nanoparticles were injected to healthy Balb/c mice. 200 µL of a 
mixture of peptide–AgNPs (prepared from Ag107) and control biotin-blocked 
AgNPs (prepared from Ag109) was administered i.v. and allowed to circulate 
for 1 or 5 hours. Animals were perfused with PBS and organs were collected 
and snap-frozen. Frozen tissue samples were thawed, digested and analyzed 
using Agilent 8800 ICP-MS. 
For ratiometric LA-ICP-MS-based biodistribution studies, mice were in-
jected i.v. with 200 µL of a mixture of peptide–AgNPs (prepared from Ag107) 
and control biotin-blocked AgNPs (prepared from Ag109). At indicated time 
points, the mice were perfused with PBS and the organs were collected, snap-
frozen, sectioned at 30 μm on Superfrost+ slides, and air-dried. Determination 
of Ag107/109 ratio in tissue sections was performed using Cetac LSX-213 G2+ 
laser ablation system (Teledyne Cetac Technologies, USA) using a HelEx 2-
volume ablation cell on Agilent 8800 ICP-MS system. 
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4.2.4.7. Experimental tumor therapy  
For experimental therapy of mice bearing s.c. U87-MG tumors, 1 × 106 cells 
were injected under the skin of dorsal flank of 11–15-week old male nude mice. 
Tumor volume [calculated with the formula: V = (width × width × length)/2] 
and mouse weight was recorded every other day. When tumors reached 100–
200 mm3 in size, the mice were divided in 4 groups (n = 6) so that the total 
volume of tumors in all groups were equal. Treatment with intravenous FAM-
LinTT1-NW, FAM-D(KLAKLAK)2-NW, or FAM-LinTT1- D(KLAKLAK)2-
NWs (at 5 mg/kg Fe per injection), or 100 μl of PBS, was started on day 36 
after tumor induction. Eight injections in total were performed on every other 
day. The study was terminated when the first tumor reached 1.5 cm3. Mice were 
sacrificed by cardiac perfusion and tissues were snap-frozen for further analysis. 
For experimental therapy of mice bearing orthotopic syngeneic 005 tumors, 
3 × 105 cells were injected in the hippocampus (coordinates: 1.5 mm laterally 
and 2 mm posteriorly from bregma and at 2.3 mm depth) of 8–12 weeks old 
C57BL/6 female mice. Ten days after transplantation of tumor cells, mice  
were divided in 5 groups (n = 6) and treated intravenously with either  
FAM-NW, FAM-LinTT1-NW, FAM-D(KLAKLAK)2-NW, or FAM-LinTT1- 
D(KLAKLAK)2-NWs (at 5 mg/kg Fe per injection), or 100 ul of PBS. Mice 
were treated for 2 weeks, 7 injections in total performed on every other day. 
Mice showing symptoms of disease were sacrificed by perfusion and tissues 
collected for further analysis.  
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5. RESULTS 
5.1. AgNP binding to immobilized receptor proteins 
Affinity targeted nanoparticles need to bind to their receptors with high speci-
ficity. For proof-of-concept experiment, well-established peptide/receptor com-
binations were used. RPARPAR peptide binds to b1b2 domain of NRP-1 and 
p32 protein is the known receptor for CGKRK peptide. SGKRK was used 
instead of CGKRK as replacing the cysteine with a serine avoids potential 
peptide-dimer formation and cysteine is not required for the binding of the 
peptide (Agemy et al. 2011). NRP-1 b1b2 with mutated binding pocket that 
prevents RPARPAR peptide binding (Teesalu et al. 2009) was used as a nega-
tive control. Nanoparticles functionalized with RPARPAR peptide (R-AgNPs) 
bound to wild-type NRP-1 protein but not to mutant NRP-1, or to p32 (Fig. 8). 
SGKRK-AgNPs (K-AgNPs) bound to immobilized p32 and not to the other two 
proteins. In this assay, both peptide-guided AgNPs showed very low back-
ground binding. 
 
 
 
 
Figure 8: Cell free binding of peptide-AgNPs to recombinant receptor proteins. 
AgNP binding experiments to recombinant proteins were carried out with wtAgNPs. 
Ni-NTA magnetic agarose beads were loaded with either the b1b2 binding domain of 
NRP-1, with p32, or with a b1b2 mutant. NPs were incubated for 1 h with the protein 
loaded beads, followed by washes, and elution with high imidazole concentration 
buffer. The eluted samples were analyzed by UV-vis spectrophotometer. The spectrum 
and maximum absorbance at 400 nm were recorded for each sample. Data represent 
mean values ± SD (n=3); *** p < 0.001 by Student’s t-test.  
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5.2. Receptor-dependent binding and uptake of 
nanoparticles by cultured tumor cells 
NRP-1 and p32 are commonly present on the surface of cancer cells. Binding 
and internalization of peptide-functionalized AgNPs was tested using two tumor 
cell lines: PPC1 prostate carcinoma cells, which express both receptors, and 
M21 melanoma cells, which express only p32. To enable the detection by flow 
cytometry and fluorescence microscopy the AgNPs were labeled with CF555 
fluorescent dye before adding the peptide. Flow cytometry-based assay showed 
that R-AgNPs bound specifically to NRP-1 expressing PPC1 cells (66 ± 1% 
positive), but not to M21 cells that do not express NPR-1 (Fig. 9). As expected, 
both cell lines bound K-AgNPs (7 ± 1% positive for M21 and 8 ± 1% for PPC-1 
cells) because p32 is present on the surface of both cell lines. Control particles 
(B-AgNPs) showed only background binding in both cell lines. 
 
 
 
Figure 9: Receptor-dependent binding and uptake of nanoparticles in PPC-1 and M21 
cells. For flow cytometry experiments, AgNPs were labeled with the fluorescent dye CF555. 
The AgNPs were tested individually for binding against two cancer cell lines: PPC-1 and 
M21. Cells were incubated for 1 h with R-, K-, or B-AgNPs at 0.2 nM. After incubation with 
AgNPs, the cells were washed, dissociated from the culture dish and analyzed for AgNP 
binding with a flow cytometer by monitoring the 555 channel: FL2. (n=3). 
 
 
Next, the uptake of nanoparticles in M21 and PPC1 cells in co-culture was 
tested to assess whether the two cell lines can be phenotypically distinguished 
based on their nanoparticle uptake pattern (Fig. 10). R-AgNPs co-localized with 
NRP-1 on the surface and in endocytic vesicles of PPC-1 cells, whereas M21 
cells did not display any signal from the R-AgNPs. In contrast, both cell lines 
bound K-AgNPs in agreement with the fact that both express p32. Control B-
AgNPs showed only weak background signal in both cell lines. These results 
demonstrate that AgNP tropism could be accurately directed by attaching 
targeting peptide ligands to the NP surface. 
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Figure 10: Receptor-dependent binding and uptake of nanoparticles by cultured 
PPC-1 and M21 cells. Fluorescence confocal microscopy of M21 and PPC-1 co-
cultured cells incubated with R-, K-, or B-AgNPs at 0.2 nM. Attached cells were 
incubated with AgNPs for 1 h. The cells were stained with anti-NRP1-1 and anti-p32 
antibodies and DAPI. AgNPs were labeled with CF555 fluorescent dye. The cells can 
be distinguished by the high amount of NRP-1 protein on the surface of PPC-1 cells and 
absence of NRP-1 in M21 cells. Note uptake of R-AgNPs in NRP-1-positive PPC-1 
cells and binding of both PPC-1 and M21 cells by K-AgNPs. Scale bar = 50 μm.  
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5.3. Identification of Alzheimer’s disease targeting peptide 
To identify homing peptides for targeting AD, in vivo T7 phage screens on AD 
mouse model hAPP-J20 were conducted (Fig. 11a). T7 CX7C library was 
intravenously injected to transgenic mouse and age-matched wild-type mice in 
four different age groups: 3, 5, 7 and 9 months. Significant difference in phage 
counts recovered from AD brain compared to wt brain was seen only for 9-
month-old age group, where AD brains with full-blown disease had four-fold 
higher phage titers than normal brains from wt mice (Fig. 11b).  
Recovered phages were analyzed by high-throughput DNA sequencing to 
map the landscape of phage displayed peptides in AD and control brains in all 
the age groups. Data mining revealed a consensus motif (A/G)BB(N/Q) (where 
B is a basic amino acid) that was enriched in all the age groups of hAPP-J20 
mice, but absent in the wt controls (Fig. 11c). One of the peptides from 9-month 
AD selected phage pool, CDAGRKQKC (“DAG”), was selected for subsequent 
studies as it agreed with the consensus sequence and contained the most 
commonly occurring amino acids in the adjacent positions. 
 
 
 
 
Figure 11: Identification of AD-homing DAG peptide by in vivo phage display. 
Schematic representation of phage screening done in transgenic hAPP-J20 mice. (a) A 
CX7C library (109 pfu) was injected intravenously in hAPP-J20 mice and wild-type (wt) 
littermate controls of different ages. After 30 minutes of circulation and perfusion to 
remove unbound phage, the hippocampus (HC) was excised, and phages were recovered 
and quantified. (b) The phage DNA was subjected to high-throughput sequencing, and 
the sequences present in the hAPP-J20 brains were compared to sequences from wt 
brains. (c) Analysis of the hAPP-J20-specific sequences revealed a consensus motif, 
(A/G)BB(N/Q) (where B is a basic amino acid). A cyclic 9-amino acid consensus 
peptide (red arrow) containing this motif (sequence CDAGRKQKC; abbreviated 
“DAG”) was chemically synthesized. 
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5.3.1. DAG peptide homing to the AD lesions modeled in mice  
To see whether the new cyclic DAG peptide is able to target AD lesions, 
synthetic fluorophore-labeled peptide was injected intravenously in hAPP-J20, 
Tg2576, and age-matched wt mice (Fig. 12). DAG peptide homed specifically 
to the brains of both AD models, whereas the brains from wt mice remained 
negative. In AD lesions, DAG accumulated in GFAP-positive activated 
astrocytes surrounding the Aβ plaques and blood vessels with adjoining glial 
cells (Fig. 12a). In the Tg2576 model, peptide showed co-localization with 
endothelial cells. Besides senile plaques, Aβ peptides are known to accumulate 
in small blood vessels in the AD brain; this phenomenon is particularly pro-
nounced in aged Tg2576 mice (Fig. 12b) (Milner et al. 2014). 
 
 
 
Figure 12: Homing of DAG peptide to the brains of AD model mice. (a) DAG 
targets activated astrocytes in AD mouse brain. FAM-DAG was intravenously injected 
to 9-month-old hAPP-J20 and wt mice and allowed to circulate for 30 minutes. The 
mice were perfused, and the brains were fixed, sectioned and stained for FAM in DAG 
(green), GFAP (red) and Aβ (magenta). The region shown is the hippocampus. The 
inset shows co-localization between DAG and GFAP, and also DAG+ and GFAP- 
regions (arrows). (b) DAG targets vessels positive for Aβ in Tg mice. DAG was in-
jected intravenously to 20-month-old Tg2576 wt mice, and processed as in panel a. The 
brain sections were stained for FAM (green), CD31 (red) and Aβ (magenta). The region 
shown is the cerebral cortex. The inset shows co-localization of DAG and Aβ (yellow, 
arrowheads). Scale bars, 50 µm (a and b), 20 µm (insets). 
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5.3.2. DAG homing to other models of neuroinflammation 
Since DAG peptide in AD models showed co-localization with activated astro-
cytes, it was decided to test the homing in other models of neuroinflammation 
where reactive astrocytes are similarly present. DAG peptide showed high 
accumulation in P13 PDX glioblastoma, where it co-localized with GFAP-
positive cells (Fig13a). For the brain injury model, DAG peptide homed to 
perilesional area containing activated astrocytes (Fig13b). Lastly, also in PD 
model DAG peptide showed preferential accumulation in GFAP-positive astro-
cytes (Fig13c). These experiments demonstrated that DAG targets activated 
astrocytes in both acute and chronic models of neuroinflammation. 
 
 
 
 
Figure 13: DAG accumulates in neuroinflammatory lesions of different etiologies. 
(a) DAG homes to glioblastoma. FAM-DAG was i.v. injected in mice bearing an angio-
genic glioblastoma derived from a patient (P13), and allowed to circulate for 30 mi-
nutes, after which the mice were intracardially perfused, the tumors were fixed, 
sectioned and immunostained for FAM (green), and GFAP (red). Scale bar, 40 µm. (b) 
DAG homes to acute brain injury. FAM-DAG was injected intravenously in mice with 
penetrating brain injury, processed as in panel a. Representative immunofluorescence 
images of brain sections from the injury area stained for FAM (green), and CD31 (red; 
left and middle panels) or GFAP (red; right panel) show stellate-shaped cells positive 
for DAG (see arrow). Scale bar, 40 µm. (c) DAG homes to the brain in a Parkinson’s 
disease mouse model. FAM-labeled DAG or control peptide was intravenously injected 
to Parkinson’s disease mice (mTHY-1-α-synuclein model, 1-year old) and processed as 
in panel a. Brain sections from DAG-injected mice were stained for FAM (green) and 
GFAP (red). DAG signal associates with activated astrocytes. Scale bar, 40 µm. 
*P<0.05. 
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5.4. Receptor-dependent homing of nanoparticles 
5.4.1. Lung targeting in healthy mice 
Systemically injected RPARPAR peptide homes to lung microvasculature in 
healthy animals (Teesalu et al. 2009). To test whether AgNPs functionalized 
with RPARPAR peptide target lungs as expected, polydisperse AgNPs particles 
with CF555 fluorescent label were used (Fig. 14). Wt-AgNPs were functio-
nalized with either RPARPAR-OH or RPARPAR-NH2 peptides. Amidated 
RPARPAR peptide is a control that does not bind to NRP-1 and thereby does 
not home to the lungs. Animals were injected with AgNPs and 5 hours after 
administration, the animals were perfused intracardially to remove unbound 
circulating particles. Fluorescence confocal imaging was used to study bio-
distribution of the AgNPs. Signal from the particles was quantified using 
ImageJ freeware. 
RPARPAR-OH-AgNPs accumulated in lungs as expected, showing 7 times 
higher fluorescence signal compared to control particles (Fig. 14). This result 
was replicated by silver enhancement and imaging by dark-field microscopy 
(not shown). 
 
 
  
Figure 14: Systemic CF555-labeled RPARPAR-OH-AgNPs home to lung tissue. 
CF555-labelled RPARPAR-OH-AgNPS and biotin-AgNPs in 200 μl PBS were intra-
venously injected to balb/c mice. After 5-h post i.v. administration, the animals were 
intracardially perfused with 15 ml PBS to wash out blood and to remove unbound 
AgNPs, and the organs of interest were snap-frozen. (A) Confocal imaging of lung 
cryosections from mice injected with CF555-AgNPs, 5 h post i.v. administration. 
Arrows point at areas of accumulation of CF555-positive RPARPAR-OH AgNPs. N=3; 
scale bars = 50μm. (B) Quantitation of the CF555 fluorescence in lung tissue sections. 
AgNP signal (red in panel A) expressed as percent of pixels with intensity above 
threshold. Five randomly chosen fields from 3 animals/group were analyzed. Data 
represent mean ± SD, ** p ˂ 0.01. 
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5.4.2. Brain targeting in healthy mice 
To verify that our AgNP platform is also suitable for targeting central nervous 
system, AgNPs functionalized with previously identified brain targeting peptide 
CAGALCY (Fan et al. 2007) were used. CAGALCY-AgNPs were injected 
intravenously and 5 h post administration biodistribution of AgNPs was 
assessed. CAGALCY-AgNPs accumulated in discrete areas in the brain paren-
chyma, quantitative analysis demonstrated ~9-fold increase of the fluorescence 
signal in the brain regions positive for these NPs than of control biotin-AgNPs 
(Fig. 15). 
 
 
Figure 15: Biodistribution of systemically administered CAGALCY-AgNPs.  
(A) Confocal imaging of tissues from mice injected i.v. with CAGALCY-functionalized 
AgNPs labeled with CF555 fluorescent dye, 5h post i.v. administration. Arrows point at 
areas of accumulation of CAGALCY AgNPs (red). Scale bars = 100μm. (B) Quanti-
tation of CF555 fluorescence in tissue sections. Ag-positive pixels/field were plotted for 
each type of nanoparticle as fold over control. N=3; 5 fields were analyzed per tissue. 
Data represent mean ± SD, **p < 0.01.  
 
 
5.4.3. DAG-mediated payload delivery to AD lesions 
To test if previously identified DAG peptide could be used for site-specific 
delivery to AD lesions, iron oxide nanoworms (IONW) were used. DAG-coated 
IONWs were administered intravenously in 9-month old hAPP-J20 and wt 
mice, and 5 h post administration NW homing to different parts of brain was 
assessed (Fig. 16). NW accumulation was seen in the hippocampus and the 
cortex of AD mice but no nanoparticle signal was seen in wt control mice. This 
result demontrated the utility of DAG peptide to carry payload to AD brains. 
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Figure 16: DAG-mediated delivery of nanoparticles to AD lesions. NWs conjugated 
with DAG (DAG-NWs) were injected i.v. into 9-month-old hAPP-J20 mice and 
allowed to circulate for 5 hours before perfusion (n=2). In the brain sections shown, 
NWs were visualized by Prussian blue staining and the sections were counterstained 
with nuclear fast red. Shown are representative sections with DAG-NWs in the 
hippocampus (top panel) and cortex (bottom panel). The controls include DAG-NWs 
injected into age-matched wt mice and non-injected hAPP-J20 mice. DG: dentate gyrus. 
Scale bar – 100 µm. DG: dentate gyrus. 
 
Mitochondrial protein p32 is intracellular in normal cells, but in highly acti-
vated cells in tumors and atherosclerotic plaques, it is also exposed on the cell-
surface. Extracellular presentation of the p32 has been detected both in tumor 
macrophages and in cancer cells (Fogal et al. 2008). It has been demonstrated 
that compared to the normal brain, malignant cells and tumor macrophages in 
lentivirally-induced 005 transgenic GBM model show upregulated cell surface 
expression of p32 (Agemy et al. 2013). To assess the relevance of p32 protein 
for GBM targeting, the distribution of total (Fig. 17a) and systemically 
accessible p32 (Fig. 17b) in a panel of four GBM models (orthotopic WT-
GBM, VEGF-KO, NCH421k and subcutaneous U87-MG) was studied. Where-
as in orthotopic tumors, the strongest signal was seen in the center of the tumor, 
in s.c.U87-MG tumors the p32 immunoreactivity was more pronounced at the 
tumor rim. To assess systemically accessible p32 rabbit polyclonal anti-p32 
antibody was administered intravenously (Fig. 17b). In mice bearing WT-GBM, 
stronger signal was visible in the tumor periphery and for U87-MG the p32 anti-
body was predominantly seen at the rim of the tumor. 
These results demonstrated upregulation of total p32 and presence of 
systemically accessible p32 in GBM models and suggested that p32 targeting 
peptides may be relevant for targeting glial tumors. 
 
5.4.4. p32-dependent precision targeting of glioblastoma 
5.4.4.1. p32 expression in glioblastoma mouse models 
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Figure 17: Expression of total and systemically accessible p32 in GBM models. (A) 
Mapping of total p32 in GBM tissue sections. Cryosections of orthotopic (WT-GBM, 
VEGF-KO- GBM, NCH421k) and subcutaneous tumors (U87) were stained with rabbit 
anti-p32 antibody and the nuclei were counterstained with DAPI. Arrows in the upper 
panel indicate p32-positive areas that colocalize with tumor nodules in GBM lesions. 
Middle panel – confocal planes with p32 staining only. Lower panel – staining with 
secondary antibody only. (B) Mapping of systemically accessible p32. Mice bearing 
orthotopic WT-GBM or subcutaneous U87 tumor were injected i.v. with 200 µg of anti-
P32 antibody and let circulate for 20 minutes. Cryosections from tumors were stained 
by secondary anti-rabbit Alexa 546 antibody to visualize the tissue-retained anti-p32 
antibody. Br – brain, Tu – tumor. Scale bars: 100 µm and 50 µm in low and high magni-
fication fields, respectively. 
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Elevated expression of total p32 and presence of extracellular p32 on GBM 
tumors demonstrated feasibility of targeting p32 in brain tumors. LinTT1 is a 
tumor homing peptide that was identified from in vitro phage display on 
immobilized p32 protein (Paasonen et al. 2016). LinTT1 is a tumor penetrating 
peptide that contains a cryptic CendR motif. After binding to p32 cell surface 
proteases cleave the peptide exposing C-terminal RPAR peptide that interacts 
with NRP-1, leading to vascular leakage and tissue penetration (Sugahara et al. 
2009; Teesalu et al. 2009) LinTT1 peptide targets tumor endothelial cells, 
macrophages, tumor lymphatics and tumor cells (Paasonen et al. 2016). 
FAM-LinTT1 or FAM alone was conjugated to iron oxide nanoworms. 
Functionalized NWs were administered in mice with phenotypically diverse 
GBM xenograft tumors. Peptide-guided NWs were accumulating in all the 
different tumors, whereas control particles demonstrated only background 
signal (Fig. 18). Increased uptake of peptide-guided NWs was seen only for 
malignant tissue; in control organs, including the brain, the fluorescent signal of 
LinTT1-NWs was at the same level with non-guided NWs. 
 
 
Figure 18: Systemic FAM-LinTT1-iron oxide nanoworms home to mouse and 
human GBM tumors implanted in nude mice. Mice bearing GBM xenografts of 
mouse (005, WT-GBM, VEGF-KO-GBM – intracranial) or of human origin (NCH421k – 
intracranial, U87-MG – subcutaneous) were injected intravenously with 7.5 mg/kg 
FAM-LinTT1-NW or FAM-NW, and allowed to circulate for 5 h followed by cardiac 
perfusion of the animals. Cryosections from subcutaneous tumor or coronal cryo-
sections from brain with GBM were stained by anti-FAM (NWs), anti-CD31 (blood 
vessels), and DAPI and visualized by confocal microscopy. Tu – tumor, BP – brain 
parenchyma. Insets show the FAM channel alone. Arrowheads indicate LinTT1-NW 
signal. Scale bars – 100 µm in low magnification panels; 50 µm in high magnification 
panel. FAM-LinTT1-NW and FAM-NW signal intensity in GBM tissue was quantified 
from 6–9 confocal images and analyzed by ImageJ. Statistical analysis was performed 
by one-way ANOVA. Error bars: standard deviation.  
5.4.4.2. LinTT1-guided NWs home to GBM tumors 
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To demonstrate that GBM homing by LinTT1 guided NPs is not dependent on 
nanoparticle platform, LinTT1 peptide was conjugated to nanoformulated 
paclitaxel-albumin. Mice bearing WT-GBM tumors were administered FAM-
LinTT1-Abraxane or control FAM-Abraxane particles without the peptide. 
Fluorescence signal of LinTT1-Abraxane was detected in tumor blood vessels 
and tumor parenchyma, whereas non-guided Abraxane showed no accumulation 
in the GBM tissue (Fig. 19). 
 
 
Figure 19: LinTT1-guided Abraxane home to GBM lesions. Systemic LinTT1-
functionalized Abraxane nanoparticles home to WT-GBM glioma. Mice bearing ortho-
topic WT-GBM glioma were injected intravenously with 0.5 mg of FAM-labeled 
LinTT1-Abraxane conjugate (A) or FAM-Abraxane (B), after 5h animals were per-
fused, and tissue snap-frozen for microscopy. Coronal cryosections from PFA-fixed 
brain with tumor were stained with anti-FAM (green, FAM-LinTT1-abraxane or FAM-
Abraxane) and anti-CD31 (red, blood vessels) antibodies, nuclei were counterstained 
with DAPI (blue), and sections were imaged by confocal microscopy. Tumor is seen as 
an area of high nuclear density. Scale bar: 100 µm. 
  
As shown before with co-culture of PPC1 cells and M21 cells, binding of 
targeted nanoparticles can be used to phenotypically distinguish cells (Fig. 10). 
To audit targeting peptide receptors on cells a highly sensitive tool based on 
isotopic AgNPs and ICP-MS quantification was developed. AgNPs were 
prepared from >99% pure silver isotopes (Ag107 or Ag109), or from wtAg-Pd 
particles that contained naturally occurring wild-type silver (wtAg), made up of 
51.8% Ag107 and 48.2% Ag109 isotopes, doped with 1% Pd. Cells were 
incubated with a mixture of homing peptide-functionalized isotopically bar-
coded AgNPs, uptake of particles was quantified by ICP-MS (Fig. 20).  
B
5.4.4.3. LinTT1 guided Abraxane homes to GBM 
 
5.5. ICP-MS-based quantification of AgNPs 
5.5.1. Phenotyping of cells using isotopically barcoded AgNPs 
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Figure 20: The principle of multiplexed ratiometric AgNP-based test system. The 
triplex system shown here is based on two targeting peptides: RPARPAR and SGKRK, 
and two biological targets: NRP-1 and p32. M21 cells express cell surface p32, whereas 
PPC-1 cells expose both p32 and NRP-1 on the cell surface. Control biotin-AgNPs do 
not bind to either cell line and serve as a negative control. When an input of three diffe-
rent AgNPs is applied to the cells, their cell binding and uptake pattern will correlate 
with availability of accessible cell surface receptor. 
 
 
To make sure that composition of NP core does not affect the functionality of 
targeted AgNPs, all the three isotopically-tagged AgNPs were functionalized 
with RPARPAR peptide and cells were incubated with the particles. Indepen-
dent of core type, all RPARPAR functionalized AgNPs bound specifically to 
PPC1 cells and not to M21 cells. ICP-MS was able to correctly identify diffe-
rent Ag isotopes and Pd doping (Fig. 21a). 
As a next step, isotopic AgNPs were functionalized with SGKRK and 
RPARPAR peptides and biotin-AgNPs were used as non-targeted control. 
Three types of AgNPs were mixed and applied to M21 and PPC1 cells. Uptake 
of AgNPs was quantified, after removing unbound and extracellular AgNPs by 
etching and washing (Fig. 21b). 75 ± 5% of AgNPs internalized by PPC1 cells 
were RPARPAR particles and the remaining 25 ± 5% were SGKRK particles. 
M21 cells were preferentially internalizing SGKRK particles (89 ± 9%) and 
only a small amount of RPARPAR particles (11 ± 1%). The amount of biotin-
AgNPs remained under detection limit, low background binding expected based 
on previous experiments was further reduced by etching of the extracellular 
particles. These results demonstrated the potential of multiplexing isotopic 
particles for assessing simultaneously the presence of multiple receptors on 
cultured cells. 
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Figure 21. Isotopic multiplexing of peptide-AgNPs after incubation with M21 and 
PPC-1 cells. A) Three isotope-tagged RPARPAR-coupled silver cores were incubated 
with PPC-1 or M21 cells for 1 hour and total bound AgNPs were quantified by ICP-MS. 
Each of the three silver cores functionalized with RPARPAR peptide showed robust 
PPC-1 binding and low M21 binding. The Pd concentration is multiplied by 50 to visua-
lize more clearly; the R-wt-Ag-Pd sample’s Pd content of 0.94 ± 0.04 ng/g is 100 times 
above the detection limit. Data represent mean values ± SD (n=3). B) Cells incubated 
with isotopically coded AgNPs (R-107AgNPs, K-109AgNPs, B-wtAg-Pd), followed by 
etching to remove the extracellular nanoparticles and quantification of the internalized 
nanoparticles by ICP-MS. PPC-1 cells demonstrated preferential uptake of R-AgNPs 
and M21 cells took up mainly K-AgNPs (n=3).  
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Cell phenotyping with isotopically barcoded AgNPs suggested applications of 
the same technology for in vivo homing studies. For proof of concept animal 
experiments with Ag107NPs and Ag109NPs were used. Ag107NPs were 
functionalized with targeting peptides and Ag109NPs were blocked with biotin. 
To determine ratio of Ag107/109 from tissue extracts ICP-MS was used that 
provides information on the average representation of the isotopic particles in 
the tissue (Fig. 22a). LA-ICP-MS analysis of frozen tissue sections was used to 
study spatial distribution of AgNPs in tissues (Fig. 22b). 
 
 
 
 
Figure 22: ICP-MS-based ratiometric analysis of homing experiments with iso-
topically-barcoded AgNPs. Balb/c mice were injected in tail vein with an equimolar 
mix of peptide-AgNPs (Ag107) and biotin-AgNPs (Ag109) in 200 μl PBS. 1 h or 5 h 
post i.v. administration, the animals were perfused with 15 ml PBS to remove free 
plasma AgNPs, and the organs of interest were snap-frozen. Tissues were subjected to 
HNO3/H2O2 extraction protocol for ICP-MS or cryosectioned for Laser Ablation ICP-
MS (LA-ICP-MS). 
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5.5.2. Application of ratiometric ICP-MS for  
AgNP in vivo homing studies 
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To study biodistribution of targeted and non-targeted isotopic AgNPs in healthy 
animals, Ag107 particles were functionalized with either lung-homing 
RPARPAR or brain-homing CAGALCY peptide. Equal amount of targeted 
Ag107-AgNPs and control biotin-AgNPs were i.v. injected in healthy animals. 
Preferential accumulation of RPARPAR-AgNPs was detected in lungs, ~9 fold 
higher amount of targeted particles were found in lungs at the one hour time 
point, after five hours the ratio over control particles had been reduced to ~5 
(Fig. 23a), which agreed well with the results from confocal imaging (Fig. 15b). 
CAGALCY-AgNPs were overrepresented in the brain but the difference was 
lower, than seen by optical imaging, this phenomenon was likely caused by 
heterogeneous homing pattern of CAGALCY and averaging of the whole brain 
extract (Fig. 23b). 
 
 
 
Figure 23: ICP-MS analysis of tissue distribution of homing peptide-functionalized 
AgNPs. (A) ICP-MS analysis of tissue distribution of RPARPAR-OH-AgNPs after 1 or 
5 h post i.v. administration. Data represent mean values ± SD (n=3). *** p ˂ 0.001, ** p 
˂ 0.01, * p ˂ 0.05. (B) ICP-MS-based analysis of tissue distribution of CAGALCY 
AgNPs. Balb/c mice were intravenously injected with an equimolar mixture of targeted 
CAGALCY AgNPs and biotin-AgNPs. 5-h post i.v. administration the animals were 
intracardially perfused with PBS, and the extracts of organs were subjected to ICP-MS 
to for relative quantitation of silver isotopes. Data represent mean ± SD (n=3), *** p ˂ 
0.001, ** p ˂ 0.01, * p ˂ 0.05. 
 
 
  
5.5.2.1. ICP-MS analysis of whole organs 
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Homing pattern of targeted nanoparticles can be very heterogeneous and if 
averaged, the difference compared to non-targeted payloads is strongly dimi-
nished. To study heterogeneous accumulation in tissues, LA-ICP-MS based 
spatial analysis of cryosections was used. Heterogeneous homing of RPARPAR-
AgNPs in the lungs was observed, more particles were accumulating in regions 
close to pulmonary vasculature and bronchioli with Ag107/109 ratio over 8 (Fig. 
24a). When Ag107/109 ratio from multiple ablation paths was averaged, the 
resulting Ag107/109 value from lungs was similar to the value obtained from 
tissue extract: ~6.1 with LA-ICP-MS vs ~5 with ICP-MS. In contrast, the ratio 
of Ag107/109 in the liver, a control organ, was ~1 with both analysis methods.  
 
 
 
Figure 24: Ratiometric LA-ICP-MS profiling in lung cryosections. (A) Balb/c mice 
were injected i.v. with 200 µL of a mixture of RPARPAR-OH-Ag107NPs and control 
biotin-Ag109NPs. At 5 h time point mice were perfused, and organs collected. Tissues 
were snap-frozen, sectioned at 30 μm, and laser ablation line scans using 40 μm spot 
were performed. Hematoxylin–eosin staining of a lung cryosections used for LA-ICP-
MS. The laser ablation path is indicated by arrow. Note the microanatomical hetero-
geneity of the lung section. The region of the graph indicated by the dashed box and 
pink shading correspond to the inset showing the laser ablation path in panel B. (B) 
Areas along the ablation path with Ag107/109 > 9 are indicated in red. Elevated 
Ag107/109 ratios are associated with vascular and bronchial structures. Data are repre-
sentative of 16 laser ablation paths. Scale bars: (A) 200 μm; (B) 100 μm. b: bronchiole, 
sm: smooth muscle, pv: pulmonary vessel. 
 
 
  
5.5.2.2. LA-ICP-MS based analysis of spatial homing 
5.5.2.2.1. In situ analysis of of RPARPAR-AgNPs in the lungs  
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To study heterogeneous accumulation of CAGALCY AgNPs in brain tissue 
LA-ICP-MS-based spatial analysis of cryosections was used. Mice injected with 
a mixture of CAGALCY and control AgNPs demonstrated overrepresentation 
of CAGALCY AgNPs in several areas in the brain, such as fibrillary tracts and 
pontine microvessels (Fig. 25). In these areas, the ratio of Ag107/109 was 
remarkably higher, between 15 and 30, compared to result from ICP-MS where 
ratio remained under 2.  
These results demonstrate the importance of tissue heterogeneity in the 
homing of targeted NPs to tissue. Spatial distribution analysis provides valuable 
information to validate new affinity ligands and study targeted therapies. 
 
 
 
Figure 25: Ratiometric LA-ICP-MS profiling on brain cryosections. Balb/c mice 
were injected i.v. with 200 µL of a mixture of CAGALCY-AgNPs (prepared from 
Ag107) and control biotin-AgNPs (prepared from Ag109). At 5 h time point, tissues 
were snap-frozen, sectioned at 30 μm, and laser ablation line scans using 40 μm spot 
were performed. ft: fibrillary tract, ml: molecular layer, gl: granular layer. 
 
 
  
5.5.2.2.2. In situ analysis of of CAGALCY-AgNPs in the brain  
64 
To study accumulation of LinTT1-AgNPs in GBM tissue, Ag109 isotopic 
particles were functionalized with inTT1 peptide and injected in equal amount 
with biotin-Ag107-NPs to s.c. U87-MG tumor bearing animals. Spatial analysis 
of tissues demonstrated elevated ratios of Ag109/107 (up to 30) in tumor areas 
rich in tumor vessels (Fig. 26) whereas isotopic ratio in liver was homogeneous 
all over the tissue.  
 
 
Figure 26: Lin-TT1-targeted silver nanoparticles home to GBM lesions. (A, B) 
Profiling of LinTT1-coupled AgNPs in U87-MG tumor by laser ablation ion-coupled 
mass spectrometry (ICP-MS). Mice bearing s.c. U87-MG tumor were injected i.v. with 
equimolar ratio of neutravidin-coated Ag109 nanoparticles coupled to biotinylated 
linTT1, and Ag107 nanoparticles coupled to biotin only. Mice were subjected to cardiac 
perfusion after 5 h of circulation of the particles, and tissue sections from snap-frozen 
organs were applied for laser ablation ICP-MS and subsequent staining with H&E. Left 
panel – tissue sections of H&E-stained tumor and liver from mouse bearing U87-MG 
subcutaneous tumor. Right panel: ratio of Ag109/107 isotopes detected from the laser 
ablation line shown in the left panel. Areas from the representative tissues and the 
respective areas on silver ratio profile are depicted with green boxes on both panels. 
Note the uniform ratio of Ag109/107 in the liver. Scale bar in H&E stained tissue 
sections: 500 µm. 
 
 
  
A
B
5.5.2.2.3. Spatial distribution analysis of LinTT1-AgNPs in  
GBM lesions 
l
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To evaluate the effect of linTT1 functionalization on anti-GBM activity of 
therapeutic NWs two different tumor models were used: s.c. U87-MG and 
orthotopic 005. Nanoworms were loaded with amphipilic proapoptotic 
D(KLAKLAK)2 peptide that destabilizes mitochondrial membranes leading to 
apoptosis. D(KLAKLAK)2 has been used in several experimental studies 
(Agemy et al. 2011; Hunt et al. 2017). In mice with s.c. U87-MG tumors, 
treatment with LinTT1- D(KLAKLAK)2-NWs suppressed tumor progression and 
tumor size at the end of treatment was significantly reduced compared to PBS 
 
Figure 27: Experimental therapy of U87-MG subcutaneous tumor-bearing mice 
with LinTT1-D(KLAKLAK)2-NW inhibits the tumor growth.  
The treatment of U87-MG-bearing mice with LinTT1-D(KLAKLAK)2-NW and control 
agents [D(KLAKLAK)2-NW, LinTT1-D(KLAKLAK)2-NWs, and PBS] was started on 
day 36 after tumor induction. The therapy consisted of 8 intravenous injections of NWs 
(5 mg/kg Fe in 100 µl) every other day. Tumor size was recorded daily, and the study 
was terminated when the first tumor reached 1.5 cm3, the maximum size allowed by the 
animal care committee. * – p < 0.01. Error bars – standard deviation. 
 
5.6. LinTT1-guided experimental therapy of GBM tumors 
group (Fig. 27). In mice with orthotopic 005 tumors, LinTT1- D(KLAKLAK)2-
NWs delayed the tumor progression and improved survival of the animals (Fig. 
28). 
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Figure 28: Experimental therapy of 005 GBM with LinTT1-D(KLAKLAK)2-NW 
inhibits the tumor growth. (A) – Starting on day 10 post tumor induction, the 005-
bearing mice received 7 i.v. injections of 5 mg/kg of LinTT1-D(KLAKLAK)2-NW, or 
control compounds [D(KLAKLAK)2-NW, LinTT1- D(KLAKLAK)2-NWs, and PBS] 
every other day. (B) – Body weight and motor functions of mice were monitored daily 
and the animals were sacrificed when they reached the limits allowed by the animal 
ethics committee, and the survival data were expressed as Kaplan-Meyer plots. (C) – 
Representative images DAPI-counterstained (blue) sections of orthotopic GBM 
(indicated by dotted line) collected on day 82 from mice treated with FAM-
D(KLAKLAK)2-NW and FAM-LinTT1- D(KLAKLAK)2-NWs. t: tumor, bp: brain 
parenchyma.  
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6. DISCUSSION 
6.1. Significance 
The identification of new affinity ligands to target CNS is important for the 
development of novel strategies to diagnose and treat nervous system dis- 
orders – as most brain disorders have no effective cure. Brain is a difficult organ 
to target as it is shielded by different protective barriers against invading patho-
gens and neurotoxic molecules. These barriers also prevent access to the brain 
of over 90% of potential neuropharmaceuticals. Nanoparticles are considered 
one of the most promising strategies to deliver drugs to the CNS. Several NP 
formulations have been reported to successfully reach the brain tissue, mainly 
when modified with surfactants or affinity ligands (De la Torre and Ceña 2018). 
Functionalizing nanoparticles with brain targeting ligands could enable 
therapeutics and imaging agents to effectively cross the blood-brain barrier and 
reach to disease sites in the brain. Targeted therapies have improved sensitivity 
and reduced off-target side effects compared to untargeted nanomedicines and 
conventional drug formulations. To develop novel targeted nanomedicines with 
a high potential to reach to clinical settings, it is important to make the right 
decisions over key features, like NP size, shape, coating and affinity ligands. 
Making these decisions is often difficult due to the lack of quantitative assays to 
evaluate in vivo homing of nanoparticles.  
 
 
6.2. Main findings 
The current study focused on identification and characterization of brain-
homing peptides that could be used to deliver cargo to brain tissue and target 
various nervous system disorders. To improve validation process of novel 
affinity ligands a highly sensitive ICP-MS-based internally controlled system 
was developed that enables silver nanoparticle quantification from cell and 
tissue lysates, and in situ analysis of tissue sections. It was demonstrated that 
previously described tumor homing peptide linTT1 increases selectivity of 
nanoparticles to malignant brain tumors and improves therapeutic efficacy of 
NPs functionalized with proapoptotic peptide. In addition, a novel homing 
peptide was identified, that recognizes cerebrovascular changes in Alzheimer`s 
disease models and homes to activated astrocytes also in other models of neuro-
logical disorders. 
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6.2.1. ICP-MS-based ratiometric system for quantitative and 
internally controlled receptor profiling 
Novel targeting ligands identified by screening combinatorial libraries, e.g. 
phage display peptide library, need to be validated. Assessment of expression 
and accessibility of the target receptors on the cell surface can be conducted by 
assessing binding and internalization of peptide-nanoparticles in the cells. A 
multiplex ultrasensitive ICP-MS-based assay was developed to quantitate nano-
particles prepared from pure silver isotopes and palladium. In proof of concept 
experiments, isotopically-barcoded AgNPs were functionalized with two 
different homing peptides (RPARPAR and GKRK) and used in internalization 
studies using cell lines with different homing peptide receptor expression. 
Amount of internalized particles was quantified by ICP-MS. It was established, 
that uptake of peptide-functionalized particles was dependent on the expression 
of the relevant receptors on the cell surface and was not affected by the exact 
composition of the nanoparticles. This highly sensitive method enables to mea-
sure relative ratios of internalized differentially functionalized nanoparticles and 
thereby provides information on the expression and availability of the relevant 
receptors.  
 
 
6.2.2. Ratiometric in vivo comparison of AgNPs is a highly 
sensitive internally controlled assay for homing studies 
Isotopically barcoded AgNPs can be used for simultaneous evaluation of the 
affinity targeting ligands in the same animal to minimize artefacts due to inter-
animal variability. Quantitative biodistribution studies using multiplexed nano-
particles would facilitate optimization of affinity ligands to target disease sites 
or specific organs. Firstly, in vivo homing of AgNPs functionalized with non-
pathogenic organ homing peptides RPARPAR (selective for lungs in normal 
mice) and CAGALCY (brain microvessels) was evaluated. Equimolar amount 
of peptide-guided Ag107 and control Ag109 particles was injected intra-
venously in the animals. Ag107/109 ratio was determined from tissue extracts 
by ICP-MS and from cryosections by LA-ICP-MS. Both methods showed 
overrepresentation of RPARPAR-NPs in the lung and CAGALCY-NPs in the 
brain, but LA-ICP-MS provided additional information about the homing within 
the tissue. Later, the LA-ICP-MS method was also used to study linTT1-AgNP 
homing to GBM lesions, showing accumulation of functionalized particles in 
tumor areas rich in blood vessels. 
Several internally controlled multiplexing approaches have been reported in 
the literature (Dahlman et al. 2017; Kunjachan et al. 2014), but they possess 
several disadvantages compared to ICP-MS based quantification. DNA-bar-
coded NPs have high sensitivity and can be used across a wide dynamic range, 
but for several reasons: these particles cannot be readily distinguished on tissue 
sections for spatial mapping, barcodes need to be protected from degradation, 
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and barcode sequences can affect PCR amplification, or NP behavior (Dahlman 
et al. 2017). NPs with different fluorophores allow noninvasive longitudinal 
homing studies, but optical imaging is not quantitative (Kunjachan et al. 2014). 
 
 
6.2.3. LinTT1 peptide guided nanoparticles accumulate  
in GBM lesions 
Precision delivery of anticancer drugs could potentially improve the prognosis 
of GBM patients. Currently, there are only two approved anticancer com-
pounds, temozolomide and nitrosourea, that are able to cross the BBB and reach 
to the cerebral tissue. Temozolomide, the standard chemotherapeutic drug of 
GBM, has only modest anticancer effect and it fails to penetrate the GBM 
lesions (Chamberlain 2010). Affinity targeted delivery of anticancer compounds 
could increase the concentration of drugs at disease site and enable to deliver 
drugs that do not readily cross the BBB.  
A novel tumor penetrating peptide, linTT1, was evaluated as an affinity 
ligand on five phenotypically diverse GBM tumor models. Functionalization 
with linTT1 peptide increased accumulation of nanoparticles at tumor site in all 
the tested models. LinTT1-NWs accumulated preferentially in stromal cell 
populations: in endothelial cells and in tumor associated macrophages (TAM). 
Experimental therapy with linTT1 guided proapoptotic iron NPs inhibited tumor 
growth and markedly improved survival of the mice compared to control 
groups. Increased amounts of TAMs have been found in stroma of various 
human malignancies (Chanmee et al. 2014). TAMs are the main cell population 
promoting tumor growth and drug resistance (Yang and Zhang 2017). Targeting 
TAMs could be a potential strategy to treat tumors that are unresponsive to 
conventional anticancer therapies. Thus, linTT1 could be used to develop 
targeted therapies to selectively kill or reprogram TAMs, and thereby improve 
the prognosis of cancer patients. Furthermore, elevated expression of p32 is 
associated with worse prognosis in GBM patients and knockdown of p32 has 
been demonstrated to slow the progression of tumor growth (Laakkonen et al. 
2004; Yenugonda et al. 2017). Future studies will show whether peptidic p32 
targeting ligands possess intrinsic antitumor activity and act in synergy with 
payload drugs promoting their therapeutic efficacy. 
 
 
6.2.4. AD peptide targets activated astrocytes in AD and  
other models of neuroinflammation 
AD is the most common age-related progressive neurodegenerative disorder 
with no effective cure. Detailed mechanistic understanding of the pathogenesis 
of AD is still missing (Du, Wang, and Geng 2018). Changes in the brain 
vasculature that lead to disruption of BBB have been reported in AD animal 
models as well as in patients with late-stage AD. Morphological and functional 
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changes in the vessels could contribute to neuronal dysfunction and neuro-
degeneration (De la Torre 2002; Zlokovic 2011). In vivo phage display screens 
on AD animal model were conducted to identify peptides that bind to molecular 
changes in the vasculature associated with AD. The novel peptide, DAG, bound 
selectively to activated astrocytes present in early stages of AD and in other 
models of neuroinflammation. DAG receptor was identified using affinity 
chromatography separation; and found to be connective tissue growth factor 
(CTGF), a matricellular protein with elevated expression in various types of 
brain injuries and in small blood vessels in the brains of human AD patients 
(Conrad et al. 2009; Spliet et al. 2003; Ueberham et al. 2003). 
DAG peptide accumulation was also seen in GBM lesions, in patient-derived 
GBM model (P13). It is worth noting that P13 model has been reported to have 
elevated CTGF expression (Bougnaud et al. 2016). P13 tumors are angiogenic 
with areas of pseudopalisading necrosis, features characteristic of clinical GBM. 
Our results suggest the potential uses for DAG peptide as a targeting ligand for 
improving imaging of neurological disorders, especially early AD and for 
delivery of drugs to brain for the treatment of neuroinflammatory conditions. 
 
 
6.3. Future directions 
Precision nanomedicine is a rapidly developing field with potential to overcome 
challenges associated with diagnosis and treatment of brain disorders. Nano-
scale systems can potentially improve imaging and treatment of neurodegene-
rative disorders and brain tumors. Nanomedicines conjugated with targeting 
ligands provide platforms for selective delivery of drugs and imaging agents to 
the CNS. Encapsulating drugs into affinity guided nanocarriers protects the 
drugs from degradation, increases their circulation time, enables crossing the 
BBB and provides controlled release at the disease site. Targeted therapies 
increase local drug concentration and protect peripheral system and surrounding 
brain tissue from toxicities. 
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7. CONCLUSIONS 
1. ICP-MS-based quantification of peptide-coated isotopically tagged AgNPs 
can be used to determine peptide receptor phenotype of cultured cells. 
2. Internally controlled ICP-MS-based AgNP quantification system makes it 
possible to study homing of targeted NPs and compare specificity of diffe-
rent homing peptides in the same animal. 
3. LA-ICP-MS based AgNP quantification method allows internally controlled 
mapping of peptide-AgNP distribution within the tissue. 
4. LinTT1 peptide guided NPs accumulate in GBM lesions and exert thera-
peutic activity in case the particles carry anticancer compounds. 
5. Phage display screens on AD model led to the discovery of homing peptide, 
DAG, which recognizes connective tissue growth factor (CTGF) in Alzhei-
mer’s brains. DAG peptide homes to the brain also in GBM, PD and 
traumatic brain injury animal models. 
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8. SUMMARY IN ESTONIAN  
Kullerpeptiidide kasutamine ajuhaiguste ravis 
Ühiskonna keskmise eluea suurenemise tulemusel kasvab vananemisega seotud 
kesknärvisüsteemi haiguste, näiteks Alzheimeri ja Parkinsoni tõve, sagedus. 
Nende haiguste puhul puudub tõhus ravi haiguse kulu peatamiseks või pat-
sientide terveks ravimiseks. Neurodegeneratiivsed haigused pole iseenesest 
letaalsed, kuid haiguse progresseeruv kulg muudab patsiendid kõrvalabist sõltu-
vaks. Seevastu ajukasvajad on väga kehva prognoosiga – hoolimata ravist ei 
ületa agressiivsemate ajukasvajate korral patsiendide elulemus 1,5 aastat.  
Kesknärvisüsteemi haiguste ravi on keeruline, kuna seda kaitsevad erinevad 
füüsilised ja funktsionaalsed barjäärid, mille eesmärgiks on takistada pato-
geenide, toksiinide ja vererakkude sisenemist ajukoesse. Olulisimad nendest 
mehhanismidest on vere-aju barjäär ning vere-tserebrospinaalvedeliku barjäär, 
millest vaid väga kindlate omadustega molekulid on võimelised läbi tungima. 
Enamikele molekulidele ning ka 99% ravimitele on need tõkked läbipääsmatud. 
Vananemisega seotud neuroloogiliste haiguste ravi parandamiseks on oluline 
parendada nende haiguste diagnoosimist. Selleks on vaja identifitseerida ja 
valideerida molekulaarseid markereid, mis võimaldavad haigusi diagnoosida 
varasemas staadiumis. Eelistatult juba enne kliiniliste sümptomite avaldumist. 
Järgmine oluline samm neuroloogiliste haiguste ravis on leida molekulaarsed 
transportsüsteemid, mille abil saaks ravimeid viia läbi kaitsva barjääri, et need 
jõuaksid haigusest haaratud koeni. Üks strateegia, mis võiks parandada ajuhai-
guste ravi, on nanotehnoloogia rakendamine. Vere-aju barjääri läbivad kuller-
molekulid on võimalik kinnitada ravimitega laaditud nanoosakeste pinnale. Sel 
viisil oleks võimalik ajukoesse transportida ka ravimeid, mis on koekultuuri 
süsteemis näidanud efektiivsust kasvajarakkude hävitamisel või neuronite 
kaitsmisel, kuid vereringesse süstituna ei suuda iseseisvalt aju kaitsvaid tõkkeid 
läbida.  
Käesoleva prekliinilise töö eesmärgiks oli leida peptiidid, mis akumulee-
ruvad ajus ning mida saab rakendada kullermolekulidena kontrastainete ja/või 
ravimite transportimiseks. Parimate kullermolekulide välja valimiseks töötasime 
välja väga täpse kvantitatiivse metoodika, mis võimaldab erinevaid kuller-
peptiide raku- ja loomkatsetes omavahel võrrelda. 
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Uurimistöö eesmärgid 
 
1. Töötada välja kvantitatiivne meetod, mis võimaldab võrrelda kullerpeptiidi-
dega funktsionaliseeritud nanoosakeste võimet rakku siseneda; 
2. Töötada välja kvantitatiivne meetod, mis võimaldab võrrelda süsteemselt 
manustatud kullerpeptiididega nanoosakeste võimet sihtmärkkoes akumulee-
ruda; 
3. Kohandada kvantitatiivne meetod sobivaks koelõikude analüüsimiseks; 
4. Hinnata kullerpeptiididega kaetud nanoosakeste võimet siseneda ajukasvaja 
koesse ning võimendada nanoravimite efektiivsust; 
5. Identifitseerida Alzheimeri tõve spetsiifiliste molekulaarsete markerite suh-
tes selektiivsed kullerpeptiidid. 
 
 
Materjal ja metoodika 
 
Käesolevas uurimistöös oli kasutusel kokku üheksa erinevat kasvajarakuliini, 
millest kolm pärinesid hiirtelt ja ülejäänud kuus inimestelt. Loomkatsetes ka-
sutati Balb/c hiiri ja atüümseid karvutuid hiiri. Kokku kasutati kuut erinevat 
multiformse glioblastoomi mudelit, kahte Alzheimeri tõve mudelit, ühte Par-
kinsoni tõve mudelit ning ühte traumaatilise ajukahjustuse loommudelit. Kõik 
loomkatsed olid kooskõlastatud vastavalt Eesti Põllumajandusministeeriumi, 
Tel Avivi ülikooli ja Sanford Burnham Prebyse meditsiiniuuringute instituudi 
vastava komisjoni poolt. Töös kasutati erinevaid varasemalt kirjeldatud kuller-
peptiide (RPARPAR, CGKRK, CAGALCY, linTT1), mis kinnitati nano-
osakeste pinnale. Nanoosakestest kasutati kahe erineva suurusega hõbeosakesi, 
raudoksiidi osakesi ja albumiin-paklitakseel nanoosakesi (Abraxane). Hõbe- ja 
raudosakesed sünteesiti vastavalt varem kirjeldatud protokollidele, Abraxane’i 
osakesed soetati valmiskujul. Peptiidid kinnitati hõbeosakestele biotiin-neutra-
vidiin interaktsiooni abil ning raudoksiidi ja Abraxane’i osakestele NHS-PEG-
maleimiidlinkeri abil. Nanoosakeste seondumist retseptorvalgule analüüsiti 
spektrofotomeetriat kasutades. Seondumiskatsed kasvajarakkudele viidi läbi 
kasutades voolutsütomeetriat, konfokaalmikroskoopiat ja induktiiv-sidestatud 
plasma mass-spektromeetriat (ICP-MS). Alzheimeri tõve (AD) peptiidi koe-
jaotumise uurimiseks kasutati AD, Parkinsoni tõve, P13 ajukasvaja ja trau-
maatilise ajukahjustuse loommudeleid, hiirtele süstiti FAM märgisega peptiidi 
ja hiljem värviti ajude ja kontrollkudede koelõike antikehadega ning koed 
visualiseeriti konfokaalmikroskoopia abil. Hõbeosakeste biojaotumise uuri-
miseks süstiti peptiidiga osakesed ja kontrollosakesed tervetesse loomadesse 
ning hiljem teostati immunohistokeemilised värvingud ja visualiseeriti konfo-
kaalmikroskoopia abil koelõigud. Kvantitatiivse analüüsimeetodi väljatööta-
miseks süstiti tervetele loomadele peptiidiga osakeste ja kontrollosakeste segu 
ning postmortaalselt eemaldatud koed jagati kaheks: üks osa külmutati ning 
teine osa kudedest lüüsiti. Kudede lüsaate analüüsiti ICP-mass-spektromeet-
riaga ning külmutatud koest tehti lõigud, mida analüüsiti laser-ablatsioon ICP- 
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mass-spektromeetria abil. Kasvajaspetsiifilise peptiidiga nanoosakeste biojaotu-
mise kvantitatiivseks analüüsiks indutseeriti hiirtele kas ortotoopsed või naha-
alused kasvajad ning loomadele süstiti peptiidiga raudoksiidi ja Abraxane’i 
osakesi. Pärast ohverdamist tehti kudedest krüolõigud, mida värviti sobivate 
antikehadega ning visualiseeriti konfokaalmikroskoopia abil. Kasvajaspetsii-
filise peptiidiga nanoosakeste biojaotumise kvantitatiivseks analüüsiks süstiti 
nahaaluste kasvajatega loomadele peptiidiga osakeste ja kontrollosakeste segu, 
koed külmutati ning tehti krüolõigud, mida kuivatati vaakumis ning seejärel 
analüüsiti laser-ablatsioon ICP-MS analüsaatoriga. Hindamaks kullerpeptiidi 
spetsiifilisust kasvajakoe suhtes ja proapoptootilise peptiidiga nanoosakeste 
efektiivsust kasvajarakkude hävitamisel viidi läbi ravikatse kahe erineva GBM 
loommudeliga. Selleks tekitati hiirtel ortotoopsed ja nahaalused kasvajad ja kui 
kasvajad olid saavutanud vajaliku suuruse, süstiti nanoosakesi sabaveeni ning 
katse lõpus võrreldi kasvajate suurust ja koehistoloogiat kontrollosakestega 
süstitud loomade kasvajatega. 
 
 
Uurimistöö peamised tulemused ja järeldused 
 
1. Töötati välja hõbedananoosakeste platvormil põhinev süsteem, mis võimal-
dab kvantiseerida erinevate peptiididega nanoosakeste võimet rakkudesse 
siseneda. Metoodika võimaldab hinnata nanoosakeste rakku sisenemiseks 
vajalike retseptorite ekspressioonitaset ja ligipääsetavust. Lisaks võimaldab 
see metoodika fenotüpiseerida segukultuurina kasvavaid rakke tänu variee-
ruvale retseptorite ekspressioonimustrile erinevatel rakuliinidel. 
2. In vitro analüüsi süsteem kohandati sobivaks in vivo katsete jaoks nii, et see 
võimaldab võrrelda erinevate kullerpeptiididega nanoosakeste võimet siht-
märkkoes akumuleeruda. Välja töötatud analüüsimeetodi abil saab mitme 
erineva peptiidiga nanoosakesi testida seguna samas loomas, lisades mee-
todile nn sisemise kontrolli ning vähendades kõrvalekallete esinemise tõe-
näosust. 
3. Laser-ablatsioon ICP-MS abil on võimalik sihtmärkkoe külmlõikudel kuller-
peptiidiga nanoosakeste biojaotumist kvantitatiivselt analüüsida.  
4. LinTT1 kasvajaspetsiifilise peptiidiga nanoosakesed akumuleerusid kasvaja-
koes kõigi viie testitud GBM mudeli puhul sõltumata nanoosakeste tüübist. 
LinTT1 nanoosakeste peamiseks sihtmärgiks olid kasvaja veresooned ja 
kasvajaseoselised makrofaagid. LinTT1 peptiidi ja proapoptootilise peptii-
diga raudoksiidi nanoosakesed olid ekperimentaalteraapia katses võrreldes 
kontrollosakestega efektiivsed, pidurdades tuumorite kasvu ning pikendes 
loomade elulemust.  
5. In vivo faagidisplei AD mudelil viis sidekoe kasvufaktor CTGFga seonduva 
DAG peptiidi avastamiseni, ning me näitasime, et DAG peptiid akumuleerub 
hiirtes glioblastoomi mudelites. 
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